Introduction {#s1}
============

A long-standing question in developmental and cell biology relates to how cells integrate mechanical and chemical signals to orchestrate the morphogenic behaviours that ensure adequate tissue patterning. During sprouting angiogenesis, the arrangement and distribution of cells rather than their numbers appear to drive morphogenesis of the vascular tree. Recent data showing unaltered remodelling in the absence of endothelial cell apoptosis and normal branching frequency across a range of endothelial cell densities support this idea ([@bib52]). In the extreme, however, too few cells will jeopardize network formation and stability ([@bib39]), whereas too many cells might compromise vessel calibre control ([@bib52]). Functional network formation therefore needs to establish the right number of cells in the right place, and distribute them such that the hierarchical branching pattern is supported. What establishes such a balance has remained unclear. Here we provide evidence for the yes-associated protein 1 (YAP) and its paralog WW domain containing transcription regulator 1 (TAZ) as critical endothelial cell autonomous regulators in this process.

YAP and TAZ, two transcriptional co-activators initially discovered as effectors of the Hippo signalling pathway, play a central role in organ size control via regulation of proliferation and apoptosis ([@bib40]; [@bib36]; [@bib55]). In confluent cells, YAP and TAZ are phosphorylated by kinases of the Hippo pathway, which induces their retention in the cytoplasm. In sparse cells, YAP and TAZ can translocate to the nucleus, where they interact with transcription factors to regulate the expression of pro-proliferative and anti-apoptotic genes. Other stimuli have been found to regulate YAP and TAZ nuclear translocation and activity -- these include, among others, G-protein coupled receptors (GPCRs) ([@bib53]), junctional proteins ([@bib18]; [@bib44]), and mechanical stimuli ([@bib15]; [@bib3]). Furthermore, besides cell proliferation and apoptosis, YAP and TAZ also regulate cell differentiation ([@bib54]), migration ([@bib58]) and actomyosin contraction ([@bib32]). In vascular development, the roles of YAP and TAZ are not fully understood. *Yap* null mutant zebrafish develop an initially normal vasculature but display increased vessel collapse and regression. *Yap/Taz* double mutant zebrafish die before the onset of circulation with severe developmental defects, precluding analysis of vascular development in this context ([@bib38]). Endothelial-specific deletion of *Yap* in mice using the Tie2-Cre transgenic line is embryonically lethal due to heart valve defects caused by failed endothelial-to-mesenchymal transition ([@bib57]). During post-natal development of the mouse retina, YAP was shown to regulate vascular branching and density by promoting the transcription of *Angiopoetin-2* (16). While these studies point towards an important role for YAP in regulating blood vessel formation and maintenance, the cellular principles and effectors of YAP/TAZ in endothelial cells in vivo, as well as the possible interplay between YAP/TAZ and the major signalling pathways regulating angiogenesis remain poorly understood.

Here, we used loss and gain of function endothelial specific mouse models to address the roles of YAP and TAZ in the vasculature. We show that YAP and TAZ are both expressed and active in sprouting ECs and critical for sprouting angiogenesis. The inducible, endothelial-specific deletion of YAP and TAZ leads to severe morphogenic defects consistent with impaired junctional remodelling in vivo. We found that the loss of YAP and TAZ decreased VE-Cadherin turnover and decreased the frequency of junction associated intermediate lamellipodia. Furthermore, the loss of YAP and TAZ decreased cell migration and increased cell-cell coupling. We also discovered that endothelial YAP and TAZ strongly inhibit BMP signalling in vitro and in vivo, and that this is mechanistically linked to the migration and permeability defects. Together our results suggest that YAP and TAZ integrate mechanical stimuli with key transcriptional regulators of endothelial sprouting and cell rearrangements during angiogenesis.

Results {#s2}
=======

YAP and TAZ have distinct expression patterns in endothelial cells of developing vessels and localise to the nucleus at the sprouting front {#s2-1}
-------------------------------------------------------------------------------------------------------------------------------------------

Immunofluorescence staining in the postnatal mouse retina showed that YAP and TAZ are distinctly expressed in the ECs of the developing vasculature ([Figure 1](#fig1){ref-type="fig"}). While YAP is evenly expressed throughout the vasculature ([Figure 1A--D](#fig1){ref-type="fig"}), the expression of TAZ is especially prominent at the sprouting front ([Figure 1E--H](#fig1){ref-type="fig"}). Furthermore, YAP is exclusively cytoplasmic in all areas of the retinal vasculature, with the exception of the sprouting front where some ECs express nuclear YAP, although at lower levels than in the cytoplasm ([Figure 1A'--D'](#fig1){ref-type="fig"}). TAZ staining signal is very low in the remodelling plexus, arteries and veins ([Figure 1E'--H'](#fig1){ref-type="fig"}); at the sprouting front, TAZ is strongly nuclear in numerous ECs ([Figure 1E](#fig1){ref-type="fig"}, green arrowheads and E'), and both nuclear and cytoplasmic in others ([Figure 1E](#fig1){ref-type="fig"}, red arrowheads). The nuclear signal of YAP and TAZ did not correlate with a tip or stalk cell phenotype; nuclear YAP and TAZ are rather present in a subset of tip and stalk ECs at the sprouting front. YAP and TAZ were also found at endothelial adherens junctions in veins and in the remodelling plexus, (yellow arrowheads in [Figure 1D' and F'](#fig1){ref-type="fig"}), as revealed by co-staining for VE-Cadherin ([Figure 1---figure supplement 1](#fig1s1){ref-type="fig"}). Together, these observations suggest that YAP/TAZ are abundant proteins in the endothelium, which are dynamically regulated during the angiogenic process.

![YAP and TAZ are expressed throughout the vasculature of developing mouse retinas, and localise to the nucleus of sprouting endothelial cells.\
Immunofluorescence staining of YAP (green, **A--D and A'--D'**) and TAZ (green, **E--H and E'--H'**) was performed in wild-type mouse retinas at post-natal day 6 (P6). Retinas were co-stained with the endothelial membrane marker Isolectin-B4 (IB4; blue) and with antibodies against the endothelial nuclei marker ERG (red). White dotted lines, outline of endothelial nuclei. Yellow dotted lines, outline of perivascular cells' nuclei. Green arrowheads, nuclear localisation of YAP and TAZ. Red arrowheads, cytoplasmic localisation of YAP and TAZ. Yellow arrowheads, junctional localisation of YAP and TAZ. Images correspond to single confocal planes. n \> 3 animals for each staining. Scale bar: 10 μm.](elife-31037-fig1){#fig1}

YAP/TAZ are required for vascular growth, branching and regularity of the network {#s2-2}
---------------------------------------------------------------------------------

To examine the cell-autonomous role of endothelial YAP and TAZ during angiogenesis we crossed mice bearing *floxed* alleles of *Yap* or *Taz* ([@bib20]) with mice expressing a tamoxifen-inducible Cre recombinase driven by the endothelial-restricted *Pdgfb* promoter (*Pdgfb-iCreERT2*) ([@bib11]). Injection of the offspring with tamoxifen induced loss of YAP and TAZ protein in ECs during post-natal vascular development, as evidenced by immunofluorescence staining ([Figure 2---figure supplement 1](#fig2s1){ref-type="fig"}).

Endothelial deletion of YAP or TAZ led to mild vascular defects ([Figure 2A,B,C,D](#fig2){ref-type="fig"}). *Yap*^fl/fl^ *Pdgfb-iCreERT2* mice (*Yap* iEC-KO) presented reduced radial expansion of the vasculature (7% ± 5.4 reduction, p=0.0123) and reduced vessel density (9% ± 4.4 reduction, p=0.0002) ([Figure 2G,H](#fig2){ref-type="fig"}). *Taz*^fl/fl^ *Pdgfb-iCreERT2* mice (*Taz* iEC-KO) did not show altered radial expansion but displayed decreased vessel density (6% ± 5.8 reduction, p=0.0214) ([Figure 2HG](#fig2){ref-type="fig"}). Neither mutant showed a change in the branching frequency of vessels ([Figure 2I](#fig2){ref-type="fig"}). Interestingly, in *Yap* iEC-KO retinas the expression of TAZ was increased and TAZ more often localised to the nucleus ([Figure 2---figure supplement 2](#fig2s2){ref-type="fig"}), suggesting compensatory regulation. *Taz* iEC-KO retinas did not however show a clear difference in YAP expression (data not shown). Deleting both proteins in compound mutant mice (*Yap*^fl/f^*Taz*^fl/fl^*Pdgfb-iCreERT2*, *YapTaz* iEC-KO) led to a dramatic defect in blood vessel development ([Figure 2E,F](#fig2){ref-type="fig"}): the retinal vasculature showed a 21% (±14, p=0.0012) decrease in radial expansion ([Figure 2G](#fig2){ref-type="fig"}), a 26% (±7.0, p\<0.0001) decrease in capillary density ([Figure 2H](#fig2){ref-type="fig"}), and a 55% (±15.4, p\<0.0001) decrease in branching frequency ([Figure 2I](#fig2){ref-type="fig"}). Interestingly, the vessel loops were not only bigger in *Yap/Taz* iEC-KO mice ([Figure 2J](#fig2){ref-type="fig"}), but also more variable in size ([Figure 2K](#fig2){ref-type="fig"}), and shape ([Figure 2L](#fig2){ref-type="fig"}) than in control mice. These results indicate that endothelial YAP and TAZ are critical for the development of a homogeneous blood vessel network and can perform redundant functions in the endothelium.

![Endothelial YAP and TAZ are required for vessel growth, branching and homogeneity of the plexus.\
(**A--F,**) Retinas from P6 *Yap* iEC-KO (**B**), *Taz* iEC-KO (**D**) and *YapTaz* iEC-KO (**F**), and respective control pups (**A,C,E**) were stained with Isolectin B4 (IB4). Scale bar: 200 μm. (**G--J**), Quantification of radial expansion (**G**), vessel density (**H**), branching frequency (**I**) and area of vessel loops (**J**) in *Yap* iEC-KO, *Taz* iEC-KO and *YapTaz* iEC-KO. Results are shown as percentage of the respective controls. Data are mean ±SD. n ≥ 5 pups. *p* values were calculated using unpaired *t*-test. \*p\<0.05; \*\*p\<0.01; \*\*\*\*p\<0.0001. (**K, L**), Quantification of the standard deviation of the area (**K**) and circularity (**L**) of the vessels loops in *Yap* iEC-KO, *Taz* iEC-KO and *YapTaz* iEC-KO retinas. Results are shown as percentage of the respective controls. Data are mean ±SD. n ≥ 5 pups. *p* values were calculated using unpaired *t*-test. \*p\<0.05; \*\*p\<0.01; \*\*\*p\<0.001\*\*\*\*p\<0.0001.\
10.7554/eLife.31037.007Figure 2---source data 1.Values for quantification of radial expansion ([Figure 2G](#fig2){ref-type="fig"}), vessel density ([Figure 2H](#fig2){ref-type="fig"}), branching frequency ([Figure 2I](#fig2){ref-type="fig"}), area of gaps ([Figure 2J](#fig2){ref-type="fig"}) and standard deviation of area ([Figure 2K](#fig2){ref-type="fig"}) and circularity ([Figure 2L](#fig2){ref-type="fig"}) of gaps in P6 *Yap* iEC-KO, *Taz* iEC-KO and *YapTaz* iEC-KO and respective control pups.Each value corresponds to the average of several measurements for one animal (see Material and methods for details).](elife-31037-fig2){#fig2}

YAP is required for endothelial cell proliferation in response to mechanical stretch {#s2-3}
------------------------------------------------------------------------------------

As YAP and TAZ display pro-proliferative and anti-apoptotic roles in many cell types ([@bib40]; [@bib36]), we evaluated whether the reduced vascularization of *Yap/Taz* iEC-KO retinas was associated with reduced cell proliferation or increased apoptosis. EC proliferation, assessed by EdU staining ([Figure 3A--C](#fig3){ref-type="fig"}), was decreased in *Yap* iEC-KO retinas (23% ± 10.0, p=0.0469), whilst not affected in *Taz* iEC-KO. Consistent with our prior results the decrease in cell proliferation was strongest in *Yap/Taz* iEC-KO retinas (33% ± 26.0, p=0.0059). Staining for cleaved caspase 3 revealed that apoptosis was unaffected by YAP/TAZ loss ([Figure 3D--F](#fig3){ref-type="fig"}).

![YAP and TAZ are required for endothelial cell proliferation in vivo and endothelial cell proliferation in response to mechanical stretch in vitro.\
(**A, B**) P6 retinal vessels labelled with IB4 (grey) and stained for EdU (red, marking S phase positive cells) and Erg (green, marking endothelial nuclei) in *YapTaz* iEC-KO (**B**) and littermate control mice (**A**). A',B', mask of Erg +cells indicating endothelial nuclei. (**A'', B''**) mask of Erg + and EdU + cells indicating proliferating endothelial cells. (**C**) Quantification of endothelial proliferation in *Yap* iEC-KO (n = 3 control/4 KO pups), *Taz* iEC-KO (n = 5 control/5 KO pups) and *YapTaz* iEC-KO (n = 8 control/7 KO pups). Number of EdU-positive and ERG-positive cells per IB4 labelled vascular area was calculated for each genotype and results are shown in percentage of the respective controls. Data are mean ±SD. *p* values were calculated using unpaired *t*-test. ns, p\>0.05; \*p\<0.05; \*\*p\<0.01. Scale bar: 50 μm. (**D, E**) P6 retinal vessels labelled with IB4 (grey) and stained for cleaved caspase 3 (red) in *YapTaz* iEC-KO (**E**) and littermate control mice (**D**).D', E', magnification of boxed area in D,E. Red arrowheads, cleaved caspase 3 positive endothelial cell. Black arrowheads, cleaved caspase 3 outside vessels. D'',E'', mask of cleaved caspase 3 positive endothelial cells. (**F**) quantification of endothelial apoptosis in *Yap* iEC-KO (n = 7 control/7 KO pups), *Taz* iEC-KO (n = 4 control/4KO pups) and *YapTaz* iEC-KO (n = 5 control/4 KO pups). Data are mean ±SD. *p* values were calculated using unpaired *t*-test. ns, p\>0.05. Scale bar: D-E 100 μm, D'-E' 50 μm. (**G**) Quantification of endothelial proliferation with increasing concentrations of VEGF treatment in YAP, TAZ and YAP/TAZ knockdown cells and control. HUVECs were treated with 0, 40, 200 or 1000 ng/mL VEGF for 24 hr and the percentage of cells in S phase was determined by flow cytometry. Graph shows the mean +SD fold change in percentage of S phase positive cells relative to 0 ng/mL of VEGF treatment. n = 3 independent experiments;\>50.000 cells analysed per experiment per condition. (**H**) Quantification of endothelial proliferation after stretch in in YAP, TAZ, YAP/TAZ and VE-Cadherin knockdown cells and control. HUVECs were subjected to cyclic stretch for 24 hr and percentage of cells in S phase was determined by EdU pulsing and immunofluorescence staining. Graph shows the mean +SD fold change in percentage of S phase positive cells of stretched to non stretched cells for each knockdown condition. n = 5 independent experiments, \>100 cells counted per experiment per condition. *p* values were calculated using unpaired *t*-test. ns, p\>0.05; \*p\<0.05.\
10.7554/eLife.31037.011Figure 3---source data 1.Values for quantification of endothelial proliferation ([Figure 3C](#fig3){ref-type="fig"}) and apoptosis ([Figure 3F](#fig3){ref-type="fig"}) in P6 *Yap* iEC-KO, *Taz* iEC-KO and *YapTaz* iEC-KO and respective control pups.Each value corresponds to the average of several measurements for one animal (see Material and methods for details). Values for quantification of endothelial proliferation in vitro in response to VEGF ([Figure 3G](#fig3){ref-type="fig"}) and stretch ([Figure 3H](#fig3){ref-type="fig"}) in YAP, TAZ and YAPTAZ knockdown cells.](elife-31037-fig3){#fig3}

To understand if YAP and TAZ were required for proliferation downstream of VEGF, we knocked down YAP and TAZ in human umbilical vein endothelial cells (HUVECs) using small interfering RNAs (siRNAs) ([Figure 3---figure supplement 1](#fig3s1){ref-type="fig"}) and measured the proliferation rate by flow cytometry after treatment with increasing concentrations of VEGF ([Figure 3G](#fig3){ref-type="fig"}). Interestingly, upon loss of YAP, TAZ or YAP/TAZ, ECs proliferated at similar or even increased rates compared to control cells. Furthermore, VEGF treatment did not alter the subcellular localisation of YAP and TAZ in HUVECs ([Figure 3---figure supplement 2](#fig3s2){ref-type="fig"}), suggesting that VEGF is not a primary regulator of their activity.

We next asked whether YAP and TAZ mediate endothelial proliferation in response to stretch -- another crucial mitogenic stimulus for the endothelium ([@bib33]). To this end, we subjected HUVECs to 24 hr of stretch and measured the proliferation rate in comparison to non-stretched, static cells treated with the same siRNAs, by EdU labelling ([Figure 3H](#fig3){ref-type="fig"}). Control cells responded to stretch with a 5-fold average increase in proliferation, and this effect was reduced upon knockdown of VE-Cadherin confirming previous observations ([@bib33]). The knockdown of YAP, but not of TAZ, led to a significant decrease in stretch-induced proliferation. The knockdown of YAP/TAZ showed a tendency to decreased proliferation in response to stretch but did not reach statistical significance. Thus YAP is required for endothelial cell proliferation in response to mechanical stimulation at cell-cell junctions.

YAP/TAZ loss leads to irregular endothelial cell distribution and haemorrhages {#s2-4}
------------------------------------------------------------------------------

Further analysis of *Yap/Taz* iEC-KO retinas revealed severe defects at the sprouting front. *Yap/Taz* iEC-KO mutant retinas had 23% (±12.3, p=0.0113) fewer angiogenic sprouts than the control ([Figure 4A,B](#fig4){ref-type="fig"} yellow asterisks and [Figure 4---figure supplement 1](#fig4s1){ref-type="fig"}). Moreover, whereas control sprouts were elongated and showed long cellular protrusions towards the non-vascularised front ([Figure 4A'](#fig4){ref-type="fig"}), sprouts in *Yap/Taz* iEC-KO retinas were rounder and lacked protrusions ([Figure 4B'](#fig4){ref-type="fig"}). The defective sprout morphology correlated with irregular spacing and frequent aggregations of ECs within the sprouts ([Figure 4B'](#fig4){ref-type="fig"}), arguing that migration and/or the rearrangement of ECs are perturbed in *Yap/Taz* mutant vessels. Additionally, the *Yap/Taz* iEC-KO vasculature displayed aberrant vessel crossings ([Figure 4C,C',C",D,D',D"](#fig4){ref-type="fig"}), suggesting that vessels may frequently have failed to anastomose or stabilize connections following sprouting, and instead passed each other. Interestingly, defects in cellular rearrangements, sprouting elongation and anastomosis have previously been associated with altered stability or dynamics of endothelial cell junctions ([@bib42]; [@bib5]; [@bib19]; [@bib31]; [@bib13]). The defects in vessel morphology were coupled to defects in function as *Yap/Taz* iEC-KO retinas displayed large haemorrhages from sprouts at the angiogenic front ([Figure 4E,E',F,F'](#fig4){ref-type="fig"}), indicating loss of junctional integrity.

![Combined loss of YAP and TAZ leads to decreased sprouting numbers and shape defects, vessel crosses, haemorrhages at the sprouting front and adherens junctions' defects in vivo.\
(**A, B**) P6 retinal vessels labelled with IB4 (green) and stained for ERG (magenta, marking endothelial nuclei) in *YapTaz* iEC-KO (**B**) and littermate control mice (**A**). Yellow asterisks mark sprouts. A',B', magnification of boxed areas in A and B. n = 9 control/9 KO pups. Scale bar: A,B 100 μm, A', B' 25 μm. (**C, D**) P6 retinal vessels labelled with IB4 in *YapTaz* iEC-KO (**D**) and littermate control mice (**E**). Red arrowheads, vessel crosses. (**C', D'**) magnification of boxed areas in C,D. C'',D'', depiction of vessels in C' and D'; different colours represent vessels in different 3D planes. n = 4 control/4 KO pups. Scale bar: C,D 100 μm, C'-D' 20 μm. (**E, F**) P6 retinal vessels labelled with IB4 (green) and stained for TER119 (magenta, marking red blood cells) in *YapTaz* iEC-KO (**F**) and littermate control mice (**E**). Red arrowheads, haemorrhages. E',F', magnification of boxed areas in E and F. n = 4 control/5 KO pups. Scale bar: E,F 1000 μm, E', F' 100 μm. (**G**, **H**), P6 retinal vessels labelled with IB4 (green) and stained for VE-Cadherin (magenta) in *YapTaz* iEC-KO (**H**) and littermate control mice (**G**). Red arrowheads, no longitudinal VE-Cadherin labelled junction along vessel axis denoting unicellular vessel segments. (**G',H', G'',H''**) magnification of boxed areas in G and H. n = 4 control/4 KO pups. Scale bar: G,H 25 μm, G',H' 5 μm, G",H" 10 μm.](elife-31037-fig4){#fig4}

Together, these results argue against the cell proliferation defect being the sole driver of the *Yap/Taz* iEC-KO phenotype and suggest that endothelial YAP/TAZ play a role in the regulation of EC junctions.

YAP/TAZ regulate adherens junction morphology and stability {#s2-5}
-----------------------------------------------------------

Staining for VE-Cadherin revealed several junctional alterations in *Yap/Taz* iEC-KO vessels ([Figure 4G--H](#fig4){ref-type="fig"}). In control retinas, cell junctions were thin and mostly linear ([Figure 4G'](#fig4){ref-type="fig"}), while in *Yap/Taz* iEC-KO retinas ECs displayed tortuous junctions ([Figure 4H'](#fig4){ref-type="fig"}). VE-Cadherin staining also unveiled profound differences in the arrangement of ECs within vessels. In control retinas, ECs were arranged into multicellular tubes, highlighted by the presence of two or more VE-Cadherin junctions running longitudinally along the axis of the vessels ([Figure 4G,G''](#fig4){ref-type="fig"}). Some unicellular segments lacking VE-Cadherin staining could also be found and always correlated with decreasing calibre, indicative of regressing vessels ([Figure 4G](#fig4){ref-type="fig"} red arrowheads) ([@bib16]). In contrast, in *Yap/Taz* iEC-KO retinas we observed many unicellular vessel segments lacking longitudinal VE-Cadherin junctions, but in vessels of normal calibre ([Figure 4H](#fig4){ref-type="fig"}, red arrowheads and H''). As junctional remodelling has been shown to be required for the cellular rearrangements that establish multicellular tubes ([@bib42]), these results suggest that YAP and TAZ regulate junctional remodelling.

VE-Cadherin staining in HUVECs after YAP, TAZ and YAP/TAZ knockdown further revealed altered junctional morphologies compared to control cells. Previous studies have correlated junctional morphology with cellular activities. In vivo, straight or linear junctions were associated with high Notch activity and stalk cell behaviour, while serrated junctions (also referred to as VE-Cadherin fingers) were found in tip cells or actively rearranging cells ([@bib5]). In vitro, VE-Cadherin fingers were shown to steer migrating ECs and couple leader and follower cells ([@bib22]), and have also been correlated with increased permeability in cell monolayers. More recently, junction associated intermediate lamellipodia (JAIL) have been identified in the sprouting vessels of the mouse retina, and linked to increased migration ([@bib8]) as well as decreased permeability in cultured ECs ([@bib7]).

To more accurately describe the differences in junctional morphology after YAP/TAZ knockdown, we defined five junctional categories: straight junctions, thick junctions, thick to reticular junctions, reticular junctions and fingers ([Figure 5E](#fig5){ref-type="fig"}). Live imaging analysis of VE-Cadherin-GFP transduced HUVECs showed that reticular junctions correspond to JAIL, and thick to reticular junctions to small JAIL. ([Figure 5---video 1](#fig5video1){ref-type="video"}). Whereas control cells showed mostly reticular junctions ([Figure 5A,F](#fig5){ref-type="fig"}), the knockdown of YAP and TAZ led to an increase in straight junctions and fingers, respectively ([Figure 5B,C,F](#fig5){ref-type="fig"}). The combined knockdown of YAP/TAZ led to an increase in both straight junctions and fingers and to a loss of reticular junctions ([Figure 5D,F](#fig5){ref-type="fig"}). In addition, the knockdown of YAP/TAZ led to junctional breaks in the monolayer, as seen by the presence of gaps in VE-Cadherin stainings ([Figure 5D](#fig5){ref-type="fig"}, red arrowheads). Together, these observations demonstrate that YAP and TAZ together are required for the formation of JAIL and reduce the formation of straight junctions and fingers.

![YAP and TAZ regulate adherens junctions' morphology, monolayer permeability and VE-Cadherin turnover in vitro.\
(**A--D**) HUVECs knocked down for YAP (**B**), TAZ (**C**) and YAP/TAZ (**D**) and control (**A**) stained for VE-Cadherin. Red arrowheads, discontinuous VE-Cadherin. Scale bar: 50 μm. (**E**) Representative patches used for manual morphological classification of adherens junctions in five categories: straight junctions, thick junctions, thick to reticular junctions, reticular junctions and fingers. (**F**) Morphological analysis of VE-Cadherin labelled cell junctions in HUVECs knocked down for YAP, TAZ and YAP/TAZ. Data are mean percentage ±SD of 3 independent experiments (two for siTAZ). n \> 140 patches of VE-Cadherin stained HUVECs per knockdown condition per experiment. *p* values were calculated using unpaired *t*-test between knocked down cells for YAP, TAZ and YAP/TAZ and control. \*p\<0.05; \*\*p\<0.01. (**G**) Permeability of YAP, TAZ and YAP/TAZ knockdown monolayers of HUVECs to 250 kDa fluorescent dextran molecules. Data are mean +SD of 3 independent experiments. *p* values were calculated using unpaired *t*-test between knocked down cells for YAP, TAZ and YAP/TAZ and control. RFU, relative fluorescence units. \*p\<0.05. (**H**, **I**) HUVECs knocked down for YAP/TAZ (**I**) and control (**H**) triple labelled with DAPI (blue), pulsed VE-Cadherin 55-7HI (red, VE-Cadherin pulse), and surface VE-Cadherin (green, VE-Cadherin staining). VE-Cadherin 55-7HI pulse was done for 30 min and cells were fixed 2 hr after end of pulse. Scale bar: 20 μm. (**J**) Representative patches used for manual classification of junctions into high, intermediate and low turnover. (**K**) Quantification of junctional turnover in YAP/TAZ knockdown cells and control. (**L**) Quantification of the percentage of high turnover junctions in each morphological category in YAP/TAZ knockdown cells and control. (**K, L**) Data are mean ±SD of 3 independent experiments. n \> 70 patches per knockdown condition per experiment. Fewer then five patches were reticular in YAP/TAZ knockdown, not allowing for reliable assessment of percentages between high, intermediate and low turnover. *p* values were calculated using unpaired *t*-test. \*p\<0.05. (**M**, **N**) Fluorescence loss after photoconversion of VE-Cadherin mEos in straight junctions of YAP/TAZ knockdown HUVECs and control HUVECs. M, VE-Cadherin mEos immobile fraction. N, VE-Cadherin mEos half-life of fluorescence loss. Data are mean ±SD of 3 independent experiments. n = 15 control cells and 16 cells YAP/TAZ knockdown cells. *p* values were calculated using unpaired *t*-test between knocked down cells for YAP/TAZ and control. \*\*p\<0.01. (**O**, **P**) HUVECs knocked down for YAP/TAZ (**P**) and control (**O**) double stained for VE-Cadherin (red) and f-actin (green, phalloidin). (**O', P'**) f-actin (black, phalloidin). Scale bar: 50 μm.\
10.7554/eLife.31037.015Figure 5---source data 1.Values for quantification of morphological ([Figure 5F](#fig5){ref-type="fig"}) and junctional turnover ([Figure 5K](#fig5){ref-type="fig"}) analysis of VE-Cadherin in HUVECs knocked down for YAP, TAZ and YAP/TAZ.Values for quantification of permeability of YAP, TAZ and YAP/TAZ knockdown monolayers of HUVECs to 250 kDa fluorescent dextran molecules ([Figure 5G](#fig5){ref-type="fig"}). Values for quantification of VE-Cadherin mEos immobile fraction ([Figure 5M](#fig5){ref-type="fig"}) and half-life of fluorescence loss ([Figure 5N](#fig5){ref-type="fig"}).](elife-31037-fig5){#fig5}

To understand whether this shift in morphology translated into a functional defect, we investigated the permeability of the monolayer to 250 kDa dextran molecules. Only the combined knockdown of YAP/TAZ led to a significant increase in permeability in comparison to the control situation ([Figure 5G](#fig5){ref-type="fig"}), suggesting that YAP/TAZ are both required for the barrier function of the endothelium and can compensate for each other in this particular role.

The dynamic rearrangements of ECs during sprouting require that cell-cell junctions are constantly assembled, rearranged and disassembled. To understand whether YAP and TAZ regulate the turnover of cell junctions, we pulse-labeled VE-Cadherin molecules at cell junctions using an antibody directly coupled to a fluorescent dye for 30 min ([Figure 5H--I](#fig5){ref-type="fig"}) ([@bib14]). The antibody was subsequently washed out and cells cultured for two more hours in normal conditions, before being fixed and stained for surface VE-Cadherin using a second fluorescent label. Comparing the two sequential VE-cadherin labels allowed us to distinguish junctions with high, intermediate and low turnover rates ([Figure 5J](#fig5){ref-type="fig"}). In control cells, 44% of patches were of high turnover junctions, 24% of intermediate turnover junctions and 32% of low turnover junctions ([Figure 5K](#fig5){ref-type="fig"}). The knockdown of YAP/TAZ significantly decreased the percentage of high turnover junctions to 14% (p=0.0387) and increased the percentage of low turnover junctions to 58%. Interestingly, we found a correlation between the morphology of junctions and VE-Cadherin turnover rates ([Figure 5L](#fig5){ref-type="fig"}): straight junctions and fingers showed the lowest turnover rate, while reticular junctions showed the highest. To understand if the different VE-Cadherin turnover observed after knockdown of YAP/TAZ was caused by a shift in morphology, we compared the turnover of VE-Cadherin within the same morphological categories. Knockdown of YAP/TAZ decreased the percentage of high turnover junctions within all morphological categories, confirming a specific defect in VE-Cadherin turnover. To further investigate how YAP and TAZ affect the turnover of VE-cadherin, we transfected HUVECs with a photo-convertible fluorescent protein tagged VE-Cadherin (VE-cadherin-mEos3.2) and measured the fluorescence loss after photo conversion in straight junctions. The knockdown of YAP/TAZ led to a significant increase in the amount of immobile VE-cadherin-mEos3.2 at the junctions ([Figure 5M](#fig5){ref-type="fig"}) without significantly affecting the half time of fluorescence loss of the mobile fraction ([Figure 5N](#fig5){ref-type="fig"}). Together, these results show that YAP/TAZ increase the turnover of adherens junctions by increasing the pool of mobile VE-Cadherin.

Immunofluorescence staining for f-actin in YAP/TAZ deficient cells ([Figure 5P,P'](#fig5){ref-type="fig"}) showed an increase in actin bundles (actin filaments along the junction and stress fibers) and a decrease in branched actin networks, in comparison with control cells ([Figure 5O,O'](#fig5){ref-type="fig"}). This result correlates with the junctional morphologies observed before, as straight junctions and fingers associate respectively with actin filaments and stress fibers ([@bib1]), while JAILs associate with branched actin ([@bib2]). Interestingly, our VE-Cadherin pulse labeling experiments showed that the junction morphologies with less turnover, straight junctions and fingers, were the ones associated with bundled actin filaments, while the morphologies with higher turnover, reticular junctions, associated with branched actin networks.

As cell junctions and the actin cytoskeleton are essential for ECs to rearrange and migrate collectively ([@bib49]), and *Yap/Taz* iEC-KO retinas presented less elongated sprouts suggestive of a migration defect, we asked whether cell migration was also regulated by YAP/TAZ.

YAP/TAZ are required for individual endothelial cell migration {#s2-6}
--------------------------------------------------------------

To address the requirement of YAP and TAZ for endothelial cell migration, we performed scratch-wound assays ([Figure 6A--H](#fig6){ref-type="fig"}). While in the control situation the wound was completely closed at 16 hr ([Figure 6A,B,I](#fig6){ref-type="fig"}), less than 50% of the wound area was closed after YAP knockdown at the same time point (p\<0.0001) ([Figure 6C,D,I](#fig6){ref-type="fig"}). A stronger effect on endothelial cell migration was observed after the knockdown of TAZ and YAP/TAZ, with less than 20% of the wound area being closed (p\<0.0001 for siTAZ vs siCTR and for siYAP +siTAZ vs siCTR) ([Figure 6E,F,G,H,I](#fig6){ref-type="fig"}).

![YAP and TAZ are required for uncoupled, individual cell migration.\
(**A--H**), Phase contrast images of YAP (**C,D**), TAZ (**E,F**) and YAP/TAZ (**G,H**) knockdown HUVECs and control (**A,B**) immediately after removing barrier to create a cell free space (**A,C,E,G**) and 16 hr later (**B,D,F,H**). (**I**), Quantification of wound closure at 16 hr. Data are mean ±SD of 3 independent experiments (8--9 biological replicates). *p* values were calculated using unpaired *t*-test between knocked down cells for YAP, TAZ or YAP/TAZ and control. \*\*\*\*p\<0.0001. (**J**, **K**), Phase contrast images of YAP/TAZ knockdown monolayer of HUVECs (**K**) and control (**J**). (**L**, **M**), Fluorescence labelling of nuclei with DAPI of YAP/TAZ knockdown monolayer of HUVECs (**M**) and control (**L**). Scale bar: 100 mm. (**L',M'**) Longest axis of nuclei. (**N**) Alignment score between nuclei pairs used for quantification of cell coordination in O. Angles made by the nuclei longest axis of a pair of nuclei were calculated; angles of 0, 45 and 90 degrees scored 1,0 and −1 in alignment. (**O**) Coordination plot of monolayers of HUVECs knocked down for YAP, TAZ and YAP and TAZ and control. Graph shows mean alignment score of all pairs of cells in the monolayer plotted against distance between them. Randomly aligned cells score 0 in mean alignment. n = 3 independent experiments,\>10.000 pairs of nuclei analysed per knockdown condition per experiment.\
10.7554/eLife.31037.018Figure 6---source data 1.Values for quantification of wound closure at 16 hr in YAP, TAZ and YAP/TAZ knockdown HUVECs and control ([Figure 6I](#fig6){ref-type="fig"}).](elife-31037-fig6){#fig6}

Given that cells aggregated at the sprouting front of *Yap/Taz* iEC-KO retinas, we wondered whether in addition to defective directional cell migration they also lacked the ability to shuffle with the neighbouring cells. Recent data illustrated that collectively migrating ECs in vitro move in streams and swirls and display straight junctions along the lateral boundaries and fingers along the front and rear ([@bib22]). To investigate collective cell migration we therefore analysed the arrangement of cells in a confluent monolayer ([Figure 6J--O](#fig6){ref-type="fig"}). Control cells displayed a cobblestone appearance without identifiable subgroups of cells ([Figure 6J](#fig6){ref-type="fig"}). In contrast, after knockdown of YAP/TAZ cells adopted elongated shapes and arranged into streams and swirls ([Figure 6K](#fig6){ref-type="fig"}). To quantity this effect we used the longest axis of the EC nucleus as a proxy for the orientation of each cell and developed a measure of monolayer coordination based on the alignment of cells with their neighbours ([Figure 6L,L',M,M', N](#fig6){ref-type="fig"}). A score of 1 would signify parallel alignment between all cells, and a score of 0 random alignment of the population. Control cells displayed higher than random alignment with their closest neighbours, but cells beyond 300 µm from each other were arranged at random ([Figure 6I](#fig6){ref-type="fig"}). While the knockdown of YAP did not affect the alignment score of cells, the knockdown of TAZ led to increased alignment. The combined knockdown of YAP/TAZ led to an even higher degree of coordination, with higher alignment scores across all distances between cells. These results suggest that YAP/TAZ promote the ability of cells to distribute individually within monolayers.

Nuclear YAP and TAZ inhibit Notch and BMP signalling in endothelial cells {#s2-7}
-------------------------------------------------------------------------

To gain insight into the nuclear function of YAP and TAZ, we generated a *Pdgfb-iCreERT2* -inducible TAZ gain-of-function mouse allele, in which a mutated version of TAZ (TAZ S89A) is introduced in the *Rosa26* locus and expressed by a *CAG* promoter following Cre-mediated excision of an upstream stop cassette ([Figure 7---figure supplement 1](#fig7s1){ref-type="fig"}). The serine-to-alanine mutation in TAZ results in enhanced nuclear TAZ localization as it escapes phosphorylation by the upstream Hippo kinase cascade ([@bib48]). The allele also expresses nuclear EGFP by means of an IRES sequence, allowing the identification of recombined cells expressing the TAZ mutant protein. *Taz* iEC-GOF retinas exhibited 25% increased sprouting (±12.2, p=0.0074) ([Figure 7A,B](#fig7){ref-type="fig"} yellow asterisks and [Figure 7C](#fig7){ref-type="fig"}) and 19% increased branching (±8.3, p=0.0012) ([Figure 7D](#fig7){ref-type="fig"}). Thus, driving nuclear TAZ expression leads in many aspects to the opposite phenotype of *Yap/Taz* iEC-KO retinas, suggesting that the loss of the nuclear function of YAP/TAZ plays a key role in the development of the observed vascular loss-of-function phenotypes.

![Nuclear YAP and TAZ inhibit Notch and BMP signalling in endothelial cells.\
(**A--B**) Retinas from P6 *Taz* iEC-GOF (**B**) and control pups (**A**) were stained for the endothelial marker PECAM (blue) and the endothelial nuclei marker ERG (red). *Taz* iEC-GOF mice express mosaically nuclear *EGFP* (nEGFP, green) marking cells expressing the TAZ gain of function mutation TAZS89A. Yellow asterisks mark sprouts. Images correspond to maximum projection of z stack. Scale bar: 50 μm. (**C**) Quantification of number of sprouts per 100 μm of sprouting front extension at P6 in *Taz* iEC-GOF mice (n = 6 pups) and littermate control mice (n = 6 pups). Data are mean ±SD. *p* values were calculated using unpaired *t*-test. \*\*p\<0.01. (**D**) Quantification of branching frequency (i.e. number of branching points per field of view) in *Taz* iEC-GOF mice (n = 6 pups) and littermate control mice (n = 6 pups). Data are mean ±SD. *p* values were calculated using unpaired *t*-test. \*\*p\<0.01. (**E**), Reverse transcriptase PCR of HUVECs transduced with adenoviruses carrying YAP (Ad*YAP*) and TAZ (Ad*TAZ*) constitutively active forms and control (Ad*GFP*). Data are mean ±SD of 3 independent experiments. *p* values were calculated using unpaired *t*-test between Ad*GFP* and Ad*YAP* or Ad*TAZ*. \*p\<0.05; \*\*p\<0.01; \*\*\*p\<0.001; \*\*\*\*p\<0.0001. (**F**) Reverse transcriptase PCR of YAP/TAZ knockdown HUVECs and control. Data are mean ±SD of 3 independent experiments. *p* values were calculated using unpaired *t*-test. \*p\<0.05; \*\*p\<0.01; \*\*\*p\<0.001; \*\*\*\*p\<0.0001. (**G**,**H**), P6 retinal vessels labelled with IB4 (green) and stained for DLL4 (magenta) in *YapTaz* iEC-KO mice (**H**) and littermate control mice (**G**). Images correspond to maximum projection of z stack. Scale bar: 50 μm. (**I**,**J**), P6 retinal vessels labelled with IB4 (blue) and stained for ERG (red, marking endothelial nuclei) and pSMAD1/5/8 (green) in *YapTaz* iEC-KO (**J**) and littermate control mice (**I**). Images correspond to single confocal planes. (**I',J'**) magnification of boxed areas in I and J. Red arrowheads, endothelial nuclei negative for pSMAD1/5/8. Green arrowheads, endothelial nuclei positive for pSMAD1/5/8. Scale bar: I,J 50 μm, I', J' 10 μm. (**K**) Quantification of endothelial cells positive for pSMAD1/5/8 at the sprouting front of the P6 retina in *YapTaz* iEC-KO (n = 3 pups) and littermate control mice (n = 3 pups). Data are mean percentage ±SD. *p* values were calculated using unpaired *t*-test. \*\*\*\*p\<0.0001.\
10.7554/eLife.31037.024Figure 7---source data 1.Values for quantification of number of sprouts ([Figure 7C](#fig7){ref-type="fig"}) and branching frequency ([Figure 7D](#fig7){ref-type="fig"}) in *Taz* iEC-GOF mice and controls.RT-PCR values of YAP and TAZ gain of function ([Figure 7E](#fig7){ref-type="fig"}) and loss of function ([Figure 7F](#fig7){ref-type="fig"}) HUVECs for Notch and BMP genes. Values for quantification of pSMAD1/5/8 staining in P6 retinas of *YapTaz* iEC-KO ([Figure 7K](#fig7){ref-type="fig"}).](elife-31037-fig7){#fig7}

To elucidate the transcriptional targets of YAP and TAZ, we performed unbiased transcriptome analysis on HUVECs transduced with adenoviruses encoding for *YAP* and *TAZ* gain-of-function mutants or *GFP* as a control (AdYAP^S127A^, AdTAZ^S89A^, AdGFP) ([Figure 7---figure supplement 2](#fig7s2){ref-type="fig"}). Forced activation of YAP and TAZ led to congruent gene expression changes including the canonical YAP/TAZ target genes *CYR61*, *ANKRD1*, and *CTGF*, as expected. Interestingly, YAP and TAZ also suppressed numerous Notch and BMP target genes. During sprouting angiogenesis, Notch and BMP9/10 signalling restrict the acquisition of a tip cell phenotype by activated ECs ([@bib23]; [@bib34]; [@bib46]; [@bib45]; [@bib12]; [@bib28]; [@bib29]). These results were confirmed by qRT-PCR analysis ([Figure 7E](#fig7){ref-type="fig"}): AdYAP^S127A^ and AdTAZ^S89A^ cells expressed significantly less *LFNG*, *DLL4* and *HES1* (Notch target genes), *SMAD6*, *UNC5B* and *ID1* (BMP target genes) and *HEY1* (a common Notch and BMP target gene) than control cells. Consistent with these findings, knockdown of YAP or TAZ lead to a substantial increase in Notch reporter activity ([Figure 7---figure supplement 3A](#fig7s3){ref-type="fig"}) and target gene expression ([Figure 7F](#fig7){ref-type="fig"}). Similar effects were observed for the BMP pathway ([Figure 7---figure supplement 3B](#fig7s3){ref-type="fig"} and [Figure 7F](#fig7){ref-type="fig"}), while TEAD-driven reporter activity and YAP/TAZ target genes were repressed ([Figure 7---figure supplement 3C](#fig7s3){ref-type="fig"} and [Figure 7F](#fig7){ref-type="fig"}).

To understand if Notch and BMP signalling were also affected in vivo, we stained *Yap/Taz* iEC-KO retinas for DLL4 and phospho-SMAD1/5/8. In control retinas, DLL4 expression was highest at the leading edge, decreasing over the first 100 µm from the sprouting front, beyond which the expression was evenly low throughout the vessels in the plexus ([Figure 7G,H](#fig7){ref-type="fig"} and [Figure 7---figure supplement 4](#fig7s4){ref-type="fig"}). In *Yap/Taz* iEC-KO retinas the expression of DLL4 at the sprouting front was higher; additionally, the area of high DLL4 was broader, decreasing for up to 200 µm from the sprouting front before flattening to the lower levels of the plexus. Moreover, staining *Yap/Taz* iEC-KO retinas for pSMAD1/5/8 showed a \~ 10 fold increase in the number of ECs positive for pSMAD1/5/8 at the sprouting front (p\<0.0001) ([Figure 7I,I', J,J',K](#fig7){ref-type="fig"}).

Together, these results identify that endothelial YAP and TAZ repress Notch and BMP signalling during angiogenesis and retinal vascular expansion.

Inhibition of BMP signalling partially rescues the cellular defects of YAP/TAZ loss in endothelial cells {#s2-8}
--------------------------------------------------------------------------------------------------------

To address whether the Notch or BMP signalling increase were responsible for the cellular defects of YAP/TAZ deficiency, we used different inhibitors to manipulate Notch and BMP signalling in cultured cells. Treatment with the Notch inhibitor DBZ corrected the Notch reporter activity increase after YAP and TAZ knockdown in HUVECs ([Figure 8A](#fig8){ref-type="fig"}), but did not affect the migration of cells in the scratch wound assay ([Figure 8B](#fig8){ref-type="fig"}).

![BMP inhibition partially rescues the cellular defects of YAPTAZ knockdown HUVECs.\
(**A**) Luciferase reporter assay for Notch activity in YAP/TAZ knockdown HUVECs and controls treated with 0.1 μM DBZ or DMSO. Data are mean ±SEM. *p* values were calculated using unpaired *t*-test. n ≥ 3 biological replicates. (**B**) Quantification of wound closure at 16 hr for HUVECs knocked down for YAP/TAZ and treated with 0.1 μM DBZ or DMSO. Data are mean ±SD. *p* values were calculated using unpaired *t*-test. n = 6 biological replicates. (**C**) Schematic of the BMP inhibitors used depicting preferential sites of inhibition. Alk1fc, ENGecd and Gremlin preferentially bind extracellular BMPs. K02288 and Ldn193189 are kinase inhibitors. (**D**) Luciferase reporter assay for BMP activity in YAP/TAZ knockdown HUVECs and controls treated with 25 ng/mL Alk1fc, 0.25 μg/mL ENGecd, 0.1 μg/mL Gremlin, 1 μM K02288, 1 μM Ldn193189 and DMSO. Data are mean ±SEM. *p* values were calculated using unpaired *t*-test. n ≥ 3 biological replicates. (**E**) Quantification of wound closure at 16 hr for HUVECs knocked down for YAP/TAZ and treated with 1 μM Ldn193189 or DMSO. Data are mean ±SD. *p* values were calculated using unpaired *t*-test. n = 6--7 biological replicates. (**F**) Permeability of HUVECs knocked down for YAP/TAZ and treated with 1 μM Ldn193189 or DMSO to 250 kDa fluorescent dextran molecules. Data are mean ±SD. RFU, relative fluorescence units. *p* values were calculated using unpaired *t*-test. n = 6 biological replicates. (**G**, **H**) HUVECs knocked down for YAP/TAZ and treated with 1 μM Ldn193189 (H) or DMSO (G) stained for VE-Cadherin. (**G', H'**) different colours mark different cells. Red arrowheads, fingers. Red arrow, reticular junction. Scale bar G, H, 50 μm. Scale bar G', H', 10 μm. (**I**) Morphological analysis of VE-Cadherin labelled cell junctions in HUVECs knocked down for YAP/TAZ and treated with 1 μM Ldn193189 or DMSO control. Data are mean ±SD. *p* values were calculated using unpaired *t*-test. n = 3 biological replicates; n ≥ 45 patches of VE-Cadherin stained HUVECs per condition per replicate.\
10.7554/eLife.31037.027Figure 8---source data 1.Values of luciferase reporter assays for Notch ([Figure 8A](#fig8){ref-type="fig"}) and BMP ([Figure 8D](#fig8){ref-type="fig"}) activity in YAP/TAZ knockdown HUVECs and controls treated with Notch or BMP inhibitors.Values for quantification of wound closure at 16 hr in YAP/TAZ knockdown HUVECs treated with Notch ([Figure 8B](#fig8){ref-type="fig"}) and BMP ([Figure 8E](#fig8){ref-type="fig"}) inhibitors. Values for quantification of permeability of YAP/TAZ knockdown HUVECs treated with 1 μM Ldn193189 ([Figure 8F](#fig8){ref-type="fig"}). Values for quantification of morphological analysis of VE-Cadherin in YAP/TAZ knockdown HUVECs treated with 1 μM Ldn193189 ([Figure 8I](#fig8){ref-type="fig"}).](elife-31037-fig8){#fig8}

To decrease BMP signaling we screened several inhibitors targeting different BMPs or BMP receptors ([Figure 8C](#fig8){ref-type="fig"}, [Supplementary file 1](#supp1){ref-type="supplementary-material"}). Only Ldn193187, an Alk2/3/1 kinase inhibitor, significantly decreased the BMP reporter activity after YAP and TAZ knockdown (p=0.0063) ([Figure 8D](#fig8){ref-type="fig"}). In comparison to control cells, the BMP reporter activity in YAP/TAZ deficient cells was 12 times higher, dropping to seven times higher after Ldn193187 treatment. To understand if the partial BMP rescue altered the cellular defects after YAP/TAZ loss, we performed the scratch wound and permeability assays using this inhibitor. Ldn193187 treatment partially rescued the migration defect of YAP/TAZ knockdown HUVECs in the scratch wound assay, significantly increasing the wound closure at 16 hr from 33 ± 3% in DMSO treated cells to 56 ± 5% in Ldn193187 treated cells (p=0.0022) ([Figure 8E](#fig8){ref-type="fig"}). Ldn193187 treatment fully rescued the permeability defect of YAP/TAZ knockdown HUVECs to 250 kDa FITC dextran molecules ([Figure 8F](#fig8){ref-type="fig"}). Staining for VE-Cadherin further showed that Ldn193187 treatment decreased the frequency of finger junctions and increased the frequency of JAIL in YAP/TAZ deficient cells ([Figure 8G--H](#fig8){ref-type="fig"}). Quantification of junction morphologies identified that Ldn193187 treatment decreased the frequency of finger junctions in YAP/TAZ deficient cells to the levels found in control cells ([Figure 8I](#fig8){ref-type="fig"} and [Figure 5F](#fig5){ref-type="fig"}, % of fingers: siYAP/TAZ DMSO, 25 ± 5%, siYAP/TAZ Ldn193187 12 ± 0.6%, siCTR: 9 ± 4%). Ldn193187 treatment also led to a 3-fold increase in thick to reticular (p=0.012) and reticular junctions (p=0.043) in YAP/TAZ knockdown cells. The frequency of straight junctions was also significantly decreased (p=0.0326) although still remaining high in comparison to control cells. Together, these results show that the BMP signaling increase is at least partially involved in the cellular defects caused by YAP/TAZ deficiency.

To gain insight into how YAP and TAZ repress BMP signalling, we analysed the gene expression of BMPs, BMP receptors and co-receptors and BMP antagonists in *YAP* and *TAZ* gain of function mutant HUVECs ([Figure 8---figure supplement 1](#fig8s1){ref-type="fig"}). As YAP and TAZ function as transcriptional co-activators, the direct targets of YAP and TAZ would be upregulated in this assay, while genes that are downregulated would represent indirect regulation. Forced activation of YAP and TAZ led to increased expression of the BMP ligands BMP2, BMP4 and BMP6, which cannot explain the increase in BMP signalling in the loss of function condition. However, we also found increased expression of the BMP antagonists *FST*, *CTGF*, *BAMBI*, *SMURF2*, *NOG* and *SMURF1*. Thus YAP and TAZ decrease BMP signalling in endothelial cells possibly by increasing the expression of BMP inhibitors.

Together, these results suggest that YAP/TAZ repress BMP activation in endothelial cells, modulating junctions and cell migration.

Discussion {#s3}
==========

The present study aimed to provide a detailed understanding of the distribution and function of endothelial YAP and TAZ in angiogenesis. Our finding that YAP and TAZ were present in the nucleus of ECs at the sprouting front of developing vessels shows parallels with other cell types where nuclear YAP and TAZ are detected in actively proliferating areas of developing tissues. Interestingly, however, YAP and TAZ show distinct expression patterns in ECs, although these proteins show a high degree of redundancy in many other cell types. While TAZ was predominantly expressed in the sprouting front where it accumulated strongly in endothelial nuclei, YAP was mostly cytoplasmic both in the sprouting front and also in more mature, remodelling vessels. Interestingly, recent work by Sakabe and colleagues showed that cytoplasmic YAP promotes endothelial cell migration ([@bib41]).

In addition to nuclear and cytoplasmic YAP and TAZ, we also detected junctional localization of these proteins in retinal vessels. A previous study by Giampietro and colleagues ([@bib18]) has shown that endothelial YAP associates with adherens junction proteins at stable junctions and that this prevents its nuclear accumulation and transcriptional activity. Whether this is also true for TAZ has previously not been addressed. A sequestration of YAP and TAZ either in the cytoplasm or bound to junctional proteins can potentially serve different and not necessarily mutually exclusive roles: preventing their nuclear activity, keeping a pool of protein ready to shuttle to the nucleus and drive gene expression, and having other cytoplasmic functions. It is not yet entirely clear what regulates the subcellular localisation of YAP and TAZ in the developing vasculature. ECs at the sprouting front and in more mature vessels have different adherens junctions, experience distinct levels of signalling from secreted angiogenic molecules and are exposed to different levels of shear stress by blood flow. In vitro, endothelial YAP and TAZ relocate to the nucleus upon disruption of cell junctions or loss of VE-Cadherin (shown for YAP by Choi and colleagues ([@bib10]) and confirmed in our analysis also for TAZ, data not shown). In the mouse retina vasculature, Cao and colleagues ([@bib8]) recently observed that endothelial cells at the sprouting front display reduced relative VE-Cadherin concentration that promotes cell-cell junction dynamics and JAIL formation. These observations nicely correlate with our own data showing the sprouting front as the area of preferential nuclear YAP/TAZ. Furthermore, we did not find junctional localisation of YAP/TAZ at the sprouting front, pointing to less sequestration of YAP/TAZ away from the nucleus by more dynamics junctions. Together, these data provide additional strength to a model in which reduced VE-Cadherin concentration at cell junctions may promote YAP and TAZ relocation to the nucleus. In zebrafish, Nakajima and colleagues ([@bib38]) showed that YAP nuclear relocation correlated with lumenisation of sprouting vessels, and they attributed this to the effect of shear stress on YAP. In the mouse retina, hemodynamic fluid laws predict that vessels at the sprouting front experience very low levels of shear ([@bib6]), arguing against YAP and TAZ being activated by shear in this model. Additionally, we found no difference in the subcellular localisation of YAP or TAZ between arteries and veins, that is, vessels that experience distinct shear stress levels. However, it is possible that local and fast changes in shear stress levels are more relevant to regulate YAP and TAZ than sustained shear. In support of this idea, YAP and TAZ appear not to respond to 12 or 24 hr of laminar shear ([@bib50]), but translocate to the nucleus after only 10 min of laminar shear ([@bib38]). Finally, although VEGF, a pro-angiogenic molecule secreted by astrocytes at the avascular front, drives endothelial proliferation and migration, we found no evidence for VEGF induced YAP and TAZ nuclear translocation, although others found opposite results ([@bib25]; [@bib51]). Other pro-angiogenic molecules, either locally produced or blood-borne, could regulate endothelial YAP and TAZ during development; future work will help clarify these questions and how different chemical and mechanical stimuli come together to regulate YAP and TAZ.

To address the cell autonomous role of YAP and TAZ we took advantage of an endothelial specific inducible Cre to inactivate YAP and/or TAZ genetically during angiogenesis. The mild phenotype of the single mutants in comparison to the drastic phenotype of the compound mutant indicates functional redundancy in the endothelium. The compound loss of endothelial YAP and TAZ leads in the mouse retina to a decrease in the radial expansion of vessels, vascular density, branching and sprouting. This phenotype could be a consequence of a decreased number of ECs caused by a proliferation defect ([@bib47]). However, our further discovery that YAP and TAZ are required to establish homogeneity in the plexus and prevent cellular aggregations suggests that endothelial YAP/TAZ signalling is not only required to provide adequate numbers of cells but is also critically involved in ensuring adequate EC distribution. We propose that endothelial YAP/TAZ operate in several mechanisms that jointly establish a balance of the right number of endothelial cells in the right place. First, endothelial YAP/TAZ drive proliferation in response to mechanical stimulation at the cell-cell junction, and not in response to VEGF. We propose that in this way endothelial YAP/TAZ provide a cell intrinsic mechanism of locally controlling cell densities, in contrast to growth factor-mediated cell proliferation instructed by the surrounding tissue. Second, endothelial YAP/TAZ increase VE-Cadherin turnover at cell-cell junctions, which we propose is essential for cells to migrate and rearrange while maintaining the endothelial barrier at the same time. This corroborates recent findings in mouse hepatocytes where YAP antagonises adherens junction stability ([@bib4]). The authors showed that YAP regulates hepatocyte adherens junctions in response to increased actomyosin contractility by increasing myosin II light chain gene expression. Accordingly, the transcriptional, nuclear role of YAP was required for junctional regulation. Together with our observations, these findings indicate the existence of a positive feedback loop where stable junctions sequester YAP and TAZ from the nucleus, therefore maintaining less junctional turnover, while remodelling junctions allow YAP and TAZ to relocate to the nucleus where they increase VE-Cadherin turnover. Our results also suggest that a high VE-Cadherin turnover at the sprouting front is required in order to maintain junctional integrity and prevent bleedings. YAP and TAZ increase the presence of JAIL (the more dynamic type of junction in our analysis) and promote branching of actin. These results are in accordance with recent data from Sakabe and colleagues reporting that YAP and TAZ increase Cdc42 activity in lamellipodia and phosphorylation of N-WASP ([@bib41]), an actin binding protein that promotes branching of actin through the activation of the Arp2/3 complex.

Molecularly, how YAP and TAZ affect this complex cell behavior is not entirely clear. Our results identify that endothelial YAP/TAZ reduce the expression of Notch and BMP signaling in ECs, yet the in vitro rescue attempts show that the Notch increase is not the reason for the YAP/TAZ phenotype. This is further corroborated by in vivo data from Kim and colleagues showing that DAPT treatment fails to restore sprouting defects in YAP/TAZ mutant retinas ([@bib25]). In contrast, reducing the increased BMP signalling experimentally corrected the permeability, and partially restored cell migration in YAP/TAZ deficient cells. This would suggest that BMP, not Notch, is a main driver of the observed cellular phenotypes. Whether the increased BMP signalling is also responsible for the phenotypes of YAP/TAZ loss of function in vivo remains to be shown. Furthermore, the full details of the involved ligands and receptors of the BMP pathway remain to be determined. Previous studies identified that BMP9/10 -- Alk1 signalling is anti-angiogenic ([@bib28]), while BMP2/4/6 - Alk2/Alk3 signalling is pro-angiogenic ([@bib30]). Given the hyposprouting phenotype and reduced cell migration, we expected an increase in BMP9/10-Alk1 signalling after YAP/TAZ loss. However, the results from the panel of BMP inhibitors instead point towards a possible increase of the BMP2/4 -- ALK3 pathway activity. However, given the notorious promiscuity of chemical inhibitors, and the different cellular context in which they are tested, this result should be seen as an indication at best. Further studies will need to address the nature of the BMP ligand/receptors and how the deregulated BMP signalling affects endothelial cell migration and adherens junctions in the context of YAP/TAZ deficiency.

Together, our results identify a role for YAP/TAZ in promoting endothelial cellular rearrangements through the regulation of junctional turnover and collectiveness of cell migration. Conceptually, linking stretch-induced proliferation (to balance cell numbers) with modulation of junctional turnover (to facilitate cell rearrangements) seems ideally suited to achieve the required balance of cell distribution for functional vascular patterning.

Materials and methods {#s4}
=====================

  -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Reagent type (species)\             Designation                     Source or reference           Identifiers   Additional information
  or resource                                                                                                     
  ----------------------------------- ------------------------------- ----------------------------- ------------- -------------------------------------------------------------------
  strain, strain background\          WT                              The Jackson laboratories                    
  (*Mus musculus*, C57BL/6J)                                                                                      

  genetic reagent (*Mus musculus*)    Yap iEC-KO, *Yap*^fl/fl^\       PMID: 27215660,\                            
                                      *Pdgfb-iCreERT2*                PMID: 18257043                              

  genetic reagent (*Mus musculus*)    Taz iEC-KO, *Taz*^fl/fl^\       PMID: 27215660,\                            
                                      *Pdgfb-iCreERT2*                PMID: 18257043                              

  genetic reagent (*Mus musculus*)    YapTaz iEC-KO, *Yap*^fl/fl^\    PMID: 27215660,\                            
                                      *Taz*^fl/fl^ *Pdgfb-iCreERT2*   PMID: 18257043                              

  genetic reagent (*Mus musculus*)    Taz iEC-GOF, *TAZ* ^S89A^\      This paper                                  Cloning information in\
                                      *EGFP Pdgfb-iCreERT2*                                                       Material and methods\
                                                                                                                  and [Figure 7---figure supplement 1](#fig7){ref-type="fig"}

  cell line (human)                   HUVEC                           PromoCell and Lonza                         

  transfected construct (human)       VE-Cadherin EGFP                PMID: 24658686                              

  transfected construct (human)       VE-Cadherin mEos3.2             This paper                                  Cloning information in\
                                                                                                                  Material and methods

  transfected construct (human)       pCMV-flag S127A YAP             Addgene, plasmid 27370                      

  transfected construct (human)       3xFLAG-pCMV5-TOPO\              Addgene, plasmid 24815                      
                                      TAZ(S89A)                                                                   

  transfected construct (human)       TEF-1 Luciferase\               PMID: 15628970                              
                                      reporter (GTIIC)                                                            

  transfected construct (murine)      RBPj Luciferase reporter        PMID: 7566092                               

  transfected construct (murine)      BRE Luciferase reporter         PMID: 11729207                              

  transfected construct (human)       FOPflash Luciferase\            PMID: 9065401                               
                                      reporter                                                                    

  transfected construct (*Renilla*)   Renilla Luciferase\             Promega, E2241                              
                                      control reporter                                                            

  antibody                            Yap (rabbit polyclonal)         ThermoFisher Scientific,\                   Dilution 1:100
                                                                      PA1-461894                                  

  antibody                            Taz (rabbit polyclonal)         Sigma, HPA007415                            Dilution 1:100

  antibody                            Erg (goat polyclonal)           Santa Cruz Biotechnology,\                  Dilution 1:100
                                                                      sc-18136                                    

  antibody                            Erg (rabbit monoclonal)         Abcam, Ab92513                              Dilution 1:1000

  antibody                            VE-Cadherin\                    BD Biosciences, 555289                      Dilution 1:100
                                      (rat monoclonal)                                                            

  antibody                            VE-Cadherin\                    Santa Cruz Biotechnology,\                  Dilution 1:100
                                      (goat polyclonal)               sc-6458                                     

  antibody                            VE-Cadherin 55--7 H1 -\         BD Biosciences, 561567                      Dilution 1:200
                                      Alexa-Fluor 647 Conjugate                                                   

  antibody                            TER-119 (rat monoclonal)        R and D Systems, MAB1125                    Dilution 1:100

  antibody                            PECAM-1 (goat polyclonal)       R and D Systems, AF3628                     Dilution 1:200

  antibody                            Cleaved caspase 3\              R and D Systems, AF835                      Dilution 1:200
                                      (rabbit polyclonal)                                                         

  antibody                            Dll4 (goat polyclonal)          R and D Systems, AF1389                     Dilution 1:100

  antibody                            pSMAD1/5/8\                     Cell Signalling, 13820S                     Dilution 1:1000
                                      (rabbit monoclonal)                                                         

  antibody                            Phalloidin-\                    ThermoFisher\                               Dilution 1:100
                                      Alexa-Fluor 488                 Scientific, A12379                          

  antibody                            Ib4-Alexa-Fluor 647\            ThermoFisher\                               Dilution 1:1000
                                      Conjugate                       Scientific, I32450                          

  antibody                            Ib4-Alexa-Fluor 488\            ThermoFisher\                               Dilution 1:1000
                                      Conjugate                       Scientific, I21411                          

  antibody                            Ib4-Alexa-Fluor 568\            ThermoFisher\                               Dilution 1:1000
                                      Conjugate                       Scientific, I21412                          

  antibody                            YAP 63.7\                       Santa Cruz Biotechnology,\                  Dilution 1:1000
                                      (mouse monoclonal)              sc-101199                                   

  antibody                            GAPDH\                          Millipore, MAB374                           Dilution 1:4000
                                      (mouse monoclonal)                                                          

  sequence-based reagent              SMART pool: siGENOME\           Dharmacon, M-012200-00-0005                 
                                      siRNA YAP                                                                   

  sequence-based reagent              SMART pool: siGENOME\           Dharmacon, M-016083-00-0005                 
                                      siRNA TAZ                                                                   

  sequence-based reagent              SMART pool: siGENOME\           Dharmacon, M-003641-01-0005                 
                                      siRNA VE-Cadherin                                                           

  sequence-based reagent              SMART pool: siGENOME\           Dharmacon, D001206-13-05                    
                                      siRNA Non targeting 1                                                       

  sequence-based reagent              Taqman probes\                  Taqman                                      [Supplementary file 3](#supp3){ref-type="supplementary-material"}
                                      for RT-qPCR                                                                 

  commercial assay or kit             Permeability assay -\           Costar, 3460                                
                                      Transwell membranes                                                         

  commercial assay or kit             Scratch wound assay -\          Ibidi, 81176                                
                                      Culture-Insert 2\                                                           
                                      Well in µ-Dish 35 mm                                                        

  commercial assay or kit             Click-iT EdU Alexa\             ThermoFisher Scientific,\                   
                                      Fluor 647 Imaging Kit           C10340                                      

  commercial assay or kit             Propidium Iodide (PI)/\         Cell Signalling, 4087                       
                                      RNase Staining Solution                                                     

  commercial assay or kit             Rneasy Mini Kit                 Quiagen, 74104                              

  commercial assay or kit             M-MLV reverse transcriptase     ThermoFisher Scientific,\                   
                                                                      28025013                                    

  commercial assay or kit             RevertAid First Strand\         ThermoFisher Scientific,\                   
                                      cDNA Synthesis Kit              K1621                                       

  commercial assay or kit             Agilent RNA 6000 Nano Kit       Agilent, 5067--1511                         

  commercial assay or kit             GeneChip Human\                 ThermoFisher Scientific,\                   
                                      Gene 2.0 ST Array               902113                                      

  chemical compound, drug             250 kDa FITC Dextran            Sigma, FD250                                

  chemical compound, drug             Lipofectamine 2000              ThermoFisher Scientific,\                   
                                                                      11668019                                    

  chemical compound, drug             Dharmafect 1\                   Dharmacon, T-2001                           
                                      transfection reagent                                                        

  chemical compound, drug             Polybrene                       Santa Cruz, sc-134220                       

  chemical compound, drug             Hydroxytamoxifen                Sigma, 7904                                 

  chemical compound, drug             DBZ                             Cayman chemicals 14627                      

  chemical compound, drug             Recombinant-hGremlin            R and D Systems, 5190-GR                    

  chemical compound, drug             Recombinant-hEndoglin           R and D Systems, 1097-EN                    

  chemical compound, drug             LDN-193189                      Cayman chemicals, 19396                     

  chemical compound, drug             K02288                          Cayman chemicals, 16678                     

  chemical compound, drug             Recombinant hAlk1fc             R and D Systems,\                           
                                                                      370-AL-100                                  

  chemical compound, drug             VEGF-165 (murine)               Prepotech, 450--32                          

  software, algorithm                 FIJI                            FIJI                                        

  software, algorithm                 Cytoplasm to nucleus\           Cell Profiler, adapted\                     
                                      translocation assay             from PMID: 17076895                         

  software, algorithm                 Mouse retina\                   This paper                                  [Source code 1](#scode1){ref-type="supplementary-material"}
                                      regularity script                                                           

  software, algorithm                 VE-Cadherin turnover\           This paper                                  [Source code 2](#scode2){ref-type="supplementary-material"}
                                      analysis script                                                             

  software, algorithm                 Patching script                 This paper                                  [Source code 3](#scode3){ref-type="supplementary-material"}

  software, algorithm                 Cell coordination\              This paper                                  [Source code 4](#scode4){ref-type="supplementary-material"}
                                      analysis script                                                             

  software, algorithm                 Dll4 gradient\                  This paper                                  [Source code 5](#scode5){ref-type="supplementary-material"}
                                      analysis script                                                             
  -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

Mice and treatments {#s4-1}
-------------------

For loss of function experiments the following mouse strains were used: *Yap ^fl/fl^* and *Taz ^fl/fl^* ([@bib20]), *Pdgfb-iCreERT2* ([@bib11]). A detailed description of the knock-in mice overexpressing the TAZ gain-of-function allele will be provided elsewhere. Briefly, *3xFLAG-TAZ^S89A^-IRES-nEGFP* with a preceding floxed STOP cassette was knocked into the *Rosa26* locus. Cre-mediated removal of the STOP sequence leads to CAG promoter-driven expression of 3xFLAG-tagged TAZ^S89A^ as well as of nuclear-localized enhanced green fluorescence protein (nEGFP). The allele was kept heterozygous in the experimental studies and was developed together with genOway.

Mice were maintained at the London Research Institute and at the Max Delbruck Center for Molecular Medicine (loss of function mice) and at the Max Planck Institute for Heart and Lung Research (gain of function mice) under standard husbandry conditions. To induce Cre-mediated recombination 4-hydroxytamoxifen (Sigma, 7904) was injected intraperitoneally (IP) (20 μL/g of 1 mg/mL solution) at postnatal day 1 and day 3 and eyes were collected at P6. In all loss and gain of function experiments control animals were littermate animals without Cre expression. Male and female mice were used for the analysis.

For endothelial cell proliferation assessment in the retina, mouse pups were injected IP 2 hours before culling with 20 uL/g of EdU solution (0.5 mg/mL; Thermo Fischer Scientific, C10340).

Cell culture {#s4-2}
------------

HUVECs from pooled donors (PromoCell) were cultured in EGM2-Bulletkit without antibiotics (Lonza) and used until passage 6. For YAP and TAZ gain of function experiments HUVECs were obtained from Lonza, cultured in endothelial basal medium (Lonza) supplemented with hydrocortisone (1 μg ml^−1^), bovine brain extract (12 μg ml^−1^), gentamicin (50 μg ml−1), amphotericin B (50 ng ml^−1^), epidermal growth factor (10 ng ml^−1^) and 10% fetal bovine serum (Life Technologies) and used until passage 4. The manufacturers authenticated the identity of HUVECs by flow cytometry for cell-type specific markers (vWF, CD31, CD105) and by functional analysis (cells positive for acetylated low density lipoprotein uptake). All cells were tested negative for mycoplasma.

For knockdown experiments, HUVECs were transfected with SMARTpool: siGENOME siRNAs purchased from Dharmacon (Yap \#M-012200-00-0005, Taz \#M-016083-00-0005, VE-Cadherin \#M-003641-01-0005 and non-targeting siRNA Pool 1 \#D001206-13-05). Briefly, subconfluent (70--80%) HUVECs were transfected with 25 nM siRNA using Dharmafect 1 transfection reagent following the protocol from the manufacturer; transfection media was removed after 24 hr and experiments were routinely performed on the third day after transfection.

To activate YAP and TAZ signalling in ECs, FLAG-YAP^S127A^- or 3x-FLAG-TAZ^S89A^-encoding adenoviruses were generated in the adenoviral type five backbone lacking the E1/E3 genes (Vector Biolabs). GFP-encoding adenoviruses were used as a control. Infections were carried out by incubating sub-confluent HUVECs (70--80%) with starvation media (EBM containing 0.1% BSA) for 4 hr followed by the addition of adenoviral particles and polybrene (Santa Cruz). After 4 hr, HUVECs were washed with Hanks Buffer for at least five times and then cultured in complete EBM media with 10% FCS and supplements overnight. All experiments were performed 24 hr post transduction.

Immunofluorescence staining {#s4-3}
---------------------------

To perform retina immunofluorescence, eyes were collected from postnatal day six mice and fixed in 4% PFA in PBS for 1 hr at 4C. Retinas were dissected in PBS and permeabilised/blocked for 1 hr at room temperature in 1% BSA, 2% FBS, 0.5% Triton X100, 0.01% Na deoxycholate and 0,02% Na Azide in PBS. Primary and secondary antibodies were incubated overnight at 4C and for 2 hr at room temperature, respectively, both in 1:1 PBS: blocking buffer. Isolectin staining was performed overnight at 4C in Pblec after retinas were equilibrated for 1 hr in Pblec at room temperature. Retinas were post-stained fixed in 2% PFA in PBS for 10 min. To mount the samples Vectashield mounting medium. (Vector Labs, H1000) or ProLong Gold (Thermo Fisher Scientific) was used. Imaging was done by laser scanning confocal microscopy (Carl Zeiss LSM700, LSM780 and Leica TCS SP8). Processing of samples was carried out in tissues from littermates under the same conditions.

For immunofluorescence in HUVECs, cells were grown in \#1.5 coverslips coated with poly-lysine and gelatin 0.2%. At the end of the experiment cells were fixed in 4% PFA for 10 min, permeabilised in 0.3% Triton-X100 in blocking buffer for 5 min and blocked in 1% BSA 20 mM Glycine in PBS for 30 min. Primary and secondary antibodies were incubated for 2 and 1 hr, respectively, in blocking buffer. Nuclei labeling was performed by incubating cells with DAPI for 5 min (Life technologies, D1306).

A list of the primary antibodies used can be found in [Supplementary file 2](#supp2){ref-type="supplementary-material"}.

Image analysis {#s4-4}
--------------

Analysis of radial expansion, capillary density, branching frequency, proliferating ECs, apoptosis and sprouting numbers was done using Fiji ([@bib43]). Radial expansion corresponds to the mean distance from the optic nerve to the sprouting front (eight measurements in tilescans of two whole retinas per animal). Capillary density corresponds to the vessel area (measured by thresholding IB4 signal) divided by the field of view area (6--8 images of (425 µm)^2^ between artery and vein per animal). Branching frequency was measured by manually counting all branching points in a field of view (4--5 images of (200 µm)^2^ between artery and vein per animal). The plexus regularity was assessed through the standard deviation of the size and the circularity of the vascular loops in the plexus (using same images as for analysis of capillary density). Vascular loops were segmented by thresholding the IB4 signal to avoid artifacts we excluded loops with a size smaller than 86 um\^2 for the analysis. Endothelial proliferation was measured by manually counting the number of EdU positive endothelial nuclei (ERG positive) and dividing by the vessel area (measured by thresholding IB4 signal) (4 images of (425 µm)^2^ containing the sprouting front and localized on top of arteries per animal). Apoptosis was measured manually by counting the number of cleaved caspase 3 positive figures and dividing by the vessel area (measured by thresholding IB4 signal) (tilescan of one whole retina per animal). The number of sprouts was measured manually (3 images of 425 × 850 µm of the sprouting front per animal). To quantify DLL4 intensity the outline of the sprouting front and the position of the arteries were manually defined using IB4 staining. Vessels were segmented by thresholding the IB4 staining in Fiji. Then, DLL4 intensity inside the vasculature was normalised with the average DLL4 intensity outside of the vasculature. Subsequently, for every pixel inside the vasculature (excluding the arteries) the distance to the sprouting front was calculated. The normalised DLL4 values within each bin were averaged (15 µm bins from 0 to 500 µm). For each retina quarter a curve was obtained, and the average and SEM of these curves was shown in the graph (one retina quarter was used per animal). To quantify pSMAD1/5/8 status the number of pSMAD1/5/8 positive endothelial nuclei was manually counted and dividing by the total number of endothelial nuclei (defined by being ERG positive) (3 images of (225 µm)^2^ containing the sprouting front were used per animal).

To analyse YAP/TAZ subcellular localisation in HUVECs we adapted a previously existing cytoplasm-to-nucleus translocation assay pipeline from Cell Profiler ([@bib9]). Briefly, YAP or TAZ staining intensity was measured both inside the nucleus of the cell and in a 12 pixels wide ring of cytoplasm grown radially from the nucleus. The nucleus localisation was determined using a DAPI mask.

Cell junction morphology analysis was done in confluent monolayers of HUVECs stained for VE-Cadherin. Five morphological categories were defined: straight, thick, thick to reticular, reticular and fingers. We acquired 5 images of (160 µm)^2^ per condition per experiment, divided each image in (16 µm)^2^ patches, and randomly grouped these patches. The classification into categories was done manually and blindly for the condition.

To analyse cell coordination we used confluent cells labelled for DAPI. The nuclei were automatically segmented using a customized Python algorithm relying on the Scikit Image Library. By fitting an ellipse to each nucleus we obtained its major and minor axis, and the angle of the major axis with the x-axis of the image was assigned to the nucleus as its orientation. This way each nucleus in the images was assigned a position given by its midpoint and an orientation. Next we analyzed the average alignment of the nuclei of two cells depending on their distance. As the nuclei don\'t have a directionality (i.e. they are nematics as opposed to vectors), the angles between two nuclei range from 0 corresponding to the nuclei being parallel, to π*/2* corresponding to them spanning a right angle. For any two cells in each image we calculated the angle and the Euclidean distance between them, and then we binned the cells depending on their distance. We introduced a parameter called \'alignment\' which is one if all cells are perfectly aligned and 0 for a completely random distribution of cell orientations.

Live imaging of VE-Cadherin-EGFP {#s4-5}
--------------------------------

24 hr after siRNA transfection, knockdown HUVECs were transduced with VE-cadherin-EGFP adenovirus as described before ([@bib5]). Briefly, cells were incubated with the virus for 24 hr and then washed three times to remove viral particles. Cells were replated onto 2-well LabTek chambered coverslips (Nunc) coated with 10 ug/mL Fibronectin (Sigma, F1141). Imaging was performed 48 hr post-transduction. Cells were imaged at 37°C under 5% CO~2~ on LSM 780 (Zeiss) using a Plan-Apochromat 63x/1.4 oil objective. Images were acquired at a 260 s time frame.

VEGF treatment and YAP/TAZ staining {#s4-6}
-----------------------------------

Confluent HUVECs were maintained in VEGF free media for 24 hr. VEGF treatment was then performed for 30 min, 1 hr and 3 hr with 0 or 40 ng/mL of VEGF-165 (PrepoTech, 450--32). Immunofluorescence staining and analysis of YAP and TAZ subcellular localisation was performed as above described.

VEGF treatment and proliferation assessment {#s4-7}
-------------------------------------------

Knockdown HUVECs were maintained in VEGF free media for 24 hr. VEGF treatment was then performed for 24 hr with 0 ng/mL, 40 ng/mL, 200 ng/mL or 1000 ng/mL of VEGF-165. Cells were pelleted, ressuspended in 90% cold Methanol and stored at −20C° before further processing. Cells were then ressuspended in Propidium Iodide/RNase staining solution (Cell signaling, 4087) for 30 min before cell cycle analysis by flow cytometry (LSRII, BD). Data was analysed using BD FACSDiva software.

Mechanical stretch application and proliferation assessment {#s4-8}
-----------------------------------------------------------

HUVECs were plated on collagen I - 0.2% gelatine-coated Bioflex plates (BF-3001C, Flexcell International Corporation). Gene knockdown was preformed as previously described. Cells were incubated in transfection media for 24 hr, and allowed to recover in fresh complete media for 4 hr. Afterwards cells were incubated for 24 hr in serum starvation media (0,1%BSA in EBM2 pure media) to form a confluent, quiescent monolayer. Cyclic stretch (0.25 Hz, 15% elongation) was then applied for 24 hr using a Flexcell FX-5000 Tension System. Control cells were placed in the same incubator but not on the Flexcell device (static conditions). EdU pulsing was performed after 20 hr of the 24 hr stretch period. At the end of the experiment cells were fixed in 4% PFA and EdU staining was performed according to the manufacturer's protocol (Click-It EdU C10340 Life Technologies). Nuclei were labelled with DAPI. Three regions of interested were acquired per sample in a Carl Zeiss LSM700 scanning confocal microscopes (Zeiss, Germany). Quantification of proliferation was done using a CellProfiler pipeline. Percentage of S phase cells was determined as percentage of EdU positive nuclei over the total number of nuclei.

Permeability assay {#s4-9}
------------------

24 hr after siRNA transfection cells were re-plated into fibronectin coated Transwell membranes (Costar 3460) at confluence and incubated for two more days to stabilize cell junctions. On the third day after transfection 0.5 mg/mL of 250 kDa FITC Dextran in cell media (Sigma FD250) was added to the top well. Fluorescence on the bottom well was measured after 6 hr in a Gemini XPS fluorescent plate reader.

Pulse chase VE-Cadherin experiment for quantification of low, intermediate and high turnover junctions {#s4-10}
------------------------------------------------------------------------------------------------------

Cells were labelled live with a non-blocking monoclonal antibody directed against extracellular VE-Cadherin and directly coupled with Alexa-Fluor647 (BD Pharmingen, \#561567, 1:200) for 30 min. Cells were then washed 2x with PBS and incubated with complete media for additional 2 hr. Cells were fixed with 4% PFA and stained for VE-Cadherin (Santa Cruz Biotechnology, \#6458, 1:200) with a secondary antibody coupled with Alexa-Fluor-488. 5 (160µm)^2^ images per condition per experiment were acquired in a Carl Zeiss LSM700 confocal laser scanning microscope using the same acquisition settings. Max projection of z stack and merging of channels was done in Fiji. Images were divided in (16 µm)^2^ patches and the patches were randomly grouped. Patches were classified into a morphological category and into low, intermediate or high turnover categories, manually and blindly for the condition.

VE-cadherin mEos3.2 cloning {#s4-11}
---------------------------

mEos3.2 cDNA ([@bib56]) was cloned downstream of full-length human VE-cadherin with a short linker (ARDPPV) and inserted into pAc-GFP-N1 backbone (Clontech) using NEBbuilder HiFi Assembly mix (NEB).

Fluorescent loss after photoconversion experiments {#s4-12}
--------------------------------------------------

HUVECs double-transfected with YAP/TAZ or scrambled siRNAs and pN1-CMV-VE-cadherin-mEos3.2 were cultured to confluency in 2-well LabTek chambered coverslips (Nunc) coated with 10 ug/mL Fibronectin (Sigma, F1141) in EGM (Promocell) supplemented with EGM2 bulletkit (Lonza). Cells were imaged at 37°C under 5% CO~2~ on LSM 780 (Zeiss) equipped with Definite Focus stabilizer. Imaging was performed using the 488 nm (green mEos3.2 component) and the 561 nm (red component) lasers using Plan-Apochromat 63x/1.4 oil objective, 0.26 × 0.26 µm pixel size and 5.09 µs pixel dwell time, 16-bit image depth. A circular region of interest (ROI) of 21 µm^2^ area was selected on straight junctions and photoconverted using the 405 nm laser. Mean fluorescence intensity in the ROI was monitored in the red channel for 15 min with 10 s resolution, while the movement of the junction was followed in the green channel.

Background signal in each frame was estimated by measuring mean intensity in non-photoconverted region and subtracted from the fluorescence-loss curves. The curves were further corrected for bleaching, using parameters estimated from fixed cells. The curves were normalized between the mean intensity in the frames before photoconversion and fluorescence intensity measured immediately after photoconversion. Normalized curves were smoothed using the moving average method; the half-time of redistribution and immobile fraction of VE-cadherin were estimated directly from the plots. Only junctions which did not substantially move or remodel during the observation time were considered for analysis. Analysis was performed using Fiji and Matlab (Mathworks).

Scratch wound assay {#s4-13}
-------------------

24 hr after siRNA transfection cells were re-plated into a scratch wound assay device (IBIDI). On the following day a cell free gap of 500 µm was created by removing the insert of the device. Images were taken immediately after removing the insert (0 hr) and after 16 hr. The cell free area was measured in Fiji and used to calculate the percentage of wound closure at 16 hr.

RNA extraction and quantitative real time-polymerase chain reaction {#s4-14}
-------------------------------------------------------------------

RNA was extracted using the RNeasy Mini Kit (Qiagen) according to the manufacturer's instructions. For HUVECs transfected with adenoviruses carrying *YAP* and *TAZ* gain of function mutations, 2 µg of total RNA were reverse transcribed to cDNA using M-MLV reverse transcriptase (ThermoFisher Scientific). For HUVECs transfected with siRNAs 90 ng of RNA were reverse transcribed using RevertAid First Strand cDNA Synthesis Kit (ThermoFisher Scientific). qRT-PCR was performed using TaqMan reagents and probes (Applied Biosystems) (listed in [Supplementary file 3](#supp3){ref-type="supplementary-material"}). qRT-PCR reactions were run on a StepOnePlus real-time PCR instrument (ThermoFisher Scientific) or Quant Studio 6 Flex (Applied Biosystems) and expression levels were normalised to human *ACTB* or human *HPRT1* using the 2deltaCT method.

Western blot {#s4-15}
------------

Protein was extracted from HUVECs using M-PER protein extraction reagent with Halt Protease and Phosphatase inhibitors (Pierce). Proteins concentration was assessed using a BCA protein assay kit (Pierce). Proteins were separated by SDS--PAGE and blotted onto nitrocellulose membranes (Bio-Rad). Membranes were probed with specific primary antibodies and then with peroxidase-conjugated secondary antibodies. The following antibodies were used: YAP 63.7 (Santa Cruz Biotechnology, sc-101199, 1:1000), GAPDH (Millipore, MAB374, 1:4000). The bands were visualized by chemiluminescence using an ECL detection kit (GE Heathcare) and a My ECL Imager (Thermo Scientific).

Dual luciferase reporter assay {#s4-16}
------------------------------

Renilla-luciferase reporter assays for TEF-1 ([@bib35]), RBPj ([@bib24]), BRE ([@bib26]; [@bib17]) and FOPflash ([@bib27])-Luciferase promoter activity were performed as follows: 48 hr after gene knockdown by siRNA HUVECs were cotransfected with 600 ng of Luciferase reporter gene construct and 300 ng of pRL-TK (Promega) using Lipofectamine2000 and incubated for 4 hr. Cell extracts were prepared 72 hr post siRNA transfection and 24 hr post Luciferase reporter transfection, and luciferase activity was measured using a dual luciferase system as described ([@bib21]). Experiments were carried out in duplicates and results were normalized to the correspondent FOPflash/Renilla measurement.

Microarray and gene set enrichment analysis {#s4-17}
-------------------------------------------

Microarray studies were performed as described([@bib37]). In brief, total RNA was extracted from HUVECs using the RNeasy kit (Qiagen) and RNA quality assessed with the 6000 nano kit and an Agilent Bioanalyser. RNA was labelled according to the Affymetrix Whole Transcript Sense Target Labeling protocol. Affymetrix GeneChip Human Gene 2.0 ST arrays were hybridized and scanned using Affymetrix protocols. Data were analysed using the Affymetrix expression console using the RMA algorithm; statistical analysis was done using DNAStar Arraystar 11. Heat maps of gene signatures were plotted using RStudio, Inc.

Notch and BMP inhibition experiments {#s4-18}
------------------------------------

A list of the reagents used, together with duration of treatment, can be found in [Supplementary file 1](#supp1){ref-type="supplementary-material"}.

Statistical analysis {#s4-19}
--------------------

Statistical analyses were performed using GraphPad Prism software and *p* value was determined using unpaired Student *t*-test between the control and the knockout/knockdown/ gain of function condition. Statistical significance was considered for p\<0.05. Values shown are mean and standard deviation was used as the dispersion measure. Biological replicates refer to individual mice for in vivo experiments and different wells for in vitro cell culture experiments; independent experiments refer to experiments done in different days; technical replicates refer to repeated measurements taken from the same sample, both for in vivo and in vitro. Exclusion of outliers was done using 'Robust regression and Outlier removal' from GraphPad Prism software, with a coefficient Q of 1%. A statistical method of sample size calculation was not used during study design. For in vivo experiments, we used an average of 6 animals per experiment, from different litters, with a minimum of 3 (detailed number of animals used in figure legends and source data). For in vitro experiments, we did a minimum of 3 independent experiments (detailed number of experiments in figure legends and source data). When technically possible the investigators were blind to the genotype of the animal or cell culture condition during sample processing and data analysis.
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Thank you for submitting your article \"YAP and TAZ regulate adherens junction dynamics and endothelial cell distribution during vascular development\" for consideration by *eLife*. Your article has been reviewed by three peer reviewers, one of whom, Reinhard Fässler (Reviewer \#1), is a member of our Board of Reviewing Editors, and the evaluation has been overseen by Fiona Watt as the Senior Editor. The following individual involved in review of your submission has agreed to reveal their identity: Guido Serini (Reviewer \#2).

Summary:

The authors report that YAP/TAZ activity is mechanically regulated in endothelial cells. This regulation of YAP/TAZ in turn controls EC proliferation and migration, VE-cadherin turnover, and Notch and BMP signalling. The reviewers spent quite a bit of time reviewing and then discussing this paper, in part because some of the findings were already published (Kim et al. JCI). However, the reviewers concluded that work on the role of YAP/TAZ in vascular biology is important, particularly since it was carried out in vivo (with loss and gain of function models) and reaches slightly different conclusions than the published work by Kim et al. Based on this discussion the Reviewing Editor has drafted this decision to help prepare a revised submission. We hope it will be possible to submit the revised version within two to three months.

Essential revisions:

1\) It is stated in the manuscript that \"VEGF treatment did not alter the subcellular localisation of YAP and TAZ in HUVECs ([Figure 3---figure supplement 2](#fig3s2){ref-type="fig"}), suggesting that VEGF is not a primary regulator of their activity\". The lack of a link between VEGF and YAP/TAZ activation could be due to the experimental design. The Materials and methods say that \"Confluent HUVECs were maintained in VEGF free media for 24h. VEGF treatment was then performed for 6h with 0ng/mL, 4ng/mL, 20ng/mL or 100ng/mL of VEGF-165\".

The VEGF treatment is probably too long to see an effect on YAP/TAZ translocation. It was previously reported that 30 min treatment with a prototypical growth factor, such as EGF, induces YAP nuclear accumulation in MCF-10A cells (Fan et al., PNAS 2013; 110: 2569-2574). Furthermore, Kim et al. treated HUVECs for 30 min, as did Wang et al. in their paper (Developmental Cell, 2017). Hence, we propose to repeat the VEGF treatment for shorter periods (30 min, 1hr, 3hrs), quantify nuclear translocation of YAP/TAZ by co-staining with a nuclear marker, and compare and discuss the findings against the published results.

2\) The VE-cadherin turnover needs to be better analysed. There is a body of evidence in the literature demonstrating that VE-cadherin internalization is key to increase vascular permeability in vitro and in vivo (Gavard and Gutkind, Nat. Cell Biol. 2006, 8:1223-1234; Gavard et al., Dev. Cell 2008, 14:25-36; Dwyer et al., Oncogene 2011, 30:190-200; Orsenigo et al., Nat. Commun. 2012, 3:1208; Yoshioka et al., Nat. Med. 2012, 18:1560-1569; Wessel, F. et al., Nat. Immunol. 2014, 15:223-230; Dorland et al., Nat. Commun. 2016, 7:12210; Di Russo et al., EMBO J. 2017, 36: 183-201). The observation that YAP/TAZ knockdown would increase endothelial cell permeability and at the same time reduce VE-cadherin endocytosis appears difficult to be reconciled in light of the above mentioned papers.

The problem is that pulse-chase experiments provide only a semi-quantitative analysis of the VE-cadherin turnover at cell-cell contacts rather than a quantitative analysis VE-cadherin endocytosis or recycling. FRAP experiments may be a more precise quantitative approach to evaluate VE-cadherin turnover at cell-cell junctions in YAP/TAZ-depleted HUVECs. We also advise to characterise the colocalization of VE-cadherin with markers of early and/or late endosomes, such as EEA1 or LAMP1, respectively.

3\) We find the YAP/TAZ link interesting, although such a link has recently been proposed by Totaro et al. (2017). The role of Notch and its epistatic relationship with YAP and/or TAZ should be somehow tackled experimentally, at least in vitro, and demonstrated not in all but at least in few key experiments. There are good reagents to manipulate Notch in cell culture and to couple it as downstream effector of YAP/TAZ (at least partially). The authors should also consider to test whether Notch serves as a mechanical mediator of (some) YAP/TAZ biology for endothelial cells.

\[Editors\' note: further revisions were requested prior to acceptance, as described below.\]

Thank you for resubmitting your work entitled \"YAP and TAZ regulate adherens junction dynamics and endothelial cell distribution during vascular development\" for further consideration at *eLife*. Your revised article has been favorably evaluated by Fiona Watt (Senior editor) and three reviewers, one of whom is a member of our Board of Reviewing Editors.

The manuscript has been improved but there are some remaining issues that need to be addressed before acceptance. In light of a recent paper published by the Schnittler lab in Nat. Commun., 2017, we would appreciate if you make the following changes in the text:

1\) Explain in the Introduction section that two classes of VE-cadherin-based adhesions exist: adherent junctions (characterizing endothelial cells of mature and already formed blood vessels) and JAILs (typical of endothelial cells of newly forming and very dynamic angiogenic blood vessels).

2\) Adopt the Schnittler nomenclature throughout the manuscript by re-defining their \"reticular junctions\" as \"large JAILs\" and \"thick to reticular junctions\" as \"small JAILs\" (as also mentioned by authors in subsection "YAP/TAZ regulate adherens junction morphology and stability"). This will allow readers to more easily compare the complementary concepts exposed in these manuscripts.

3\) Mention that the preferential nuclear YAP/TAZ localization in endothelial cells of the sprouting front of the developing retinal vasculature nicely fit with the observation reported by Cao et al. (Nat. Commun., 2017, 8:2210). Indeed, in [Figure 1](#fig1){ref-type="fig"} Cao et al. show that endothelial cells of blood vessels localized at the sprouting front of the developing retina are elongated and display a reduced relative VE-cadherin concentration that promotes cell-to-cell junction dynamics and JAIL formation. Altogether, these data would provide additional strength to a model in which reduction of VE cadherin concentration at endothelial cell-to-cell junctions may promote YAP and TAZ relocation to the nucleus.

10.7554/eLife.31037.043

Author response

> Essential revisions:
>
> 1\) It is stated in the manuscript that \"VEGF treatment did not alter the subcellular localisation of YAP and TAZ in HUVECs ([Figure 3---figure supplement 2](#fig3s2){ref-type="fig"}), suggesting that VEGF is not a primary regulator of their activity\". The lack of a link between VEGF and YAP/TAZ activation could be due to the experimental design. The Materials and methods say that \"Confluent HUVECs were maintained in VEGF free media for 24h. VEGF treatment was then performed for 6h with 0ng/mL, 4ng/mL, 20ng/mL or 100ng/mL of VEGF-165\".
>
> The VEGF treatment is probably too long to see an effect on YAP/TAZ translocation. It was previously reported that 30 min treatment with a prototypical growth factor, such as EGF, induces YAP nuclear accumulation in MCF-10A cells (Fan et al., PNAS 2013; 110: 2569-2574). Furthermore, Kim et al. treated HUVECs for 30 min, as did Wang et al. in their paper (Developmental Cell, 2017). Hence, we propose to repeat the VEGF treatment for shorter periods (30 min, 1hr, 3hrs), quantify nuclear translocation of YAP/TAZ by co-staining with a nuclear marker, and compare and discuss the findings against the published results.

As our VEGF experiments were conflicting with the previously published results by Kim et al. (1) and Wang et al. (2), we repeated the experiments using the shorter periods of treatment as suggested by the reviewers and quantified translocation of YAP/TAZ by co-staining with the nuclear marker DAPI. We also noticed on reviewing our experiments that we were not using 0-4-20-100ng/mL as stated, but instead 0-40-200-1000ng/mL of VEGF-165, which we corrected in the manuscript accordingly. We therefore repeated the staining for YAP and TAZ using 40ng/mL VEGF-165 concentration, as this was most equivalent to the concentration used in the referred papers (50ng/mL), and evaluated YAP/TAZ nuclear to cytoplasmic ratio after 30 min, 1h and 3h treatment. The results showed no differences upon VEGF treatment at any time point (new [Figure 3--figure supplement 2](#fig3s2){ref-type="fig"}).

In Wang et al. (2) cells were cultured routinely in 10% FBS, and starved overnight in serum free media before VEGF stimulation. Because our starvation media contained 2% FBS, we repeated the experiment doing 24h of serum starvation (EBM2 pure -- without added growth factors and FBS -- supplemented with 0.1% BSA) ([Author response image 1](#respfig1){ref-type="fig"}). Also in these conditions quantification revealed no activation of YAP/TAZ upon VEGF treatment.

![VEGF treatment does not affect YAP and TAZ subcellular localisation.\
Confluent HUVECs were starved in FBS free media (EBM2 0.1% BSA) and treated with 40ng/mL of VEGF for 30 min (B, F), 1h (C,G) and 3h (D, H) or control (A, E) and stained for YAP (**A-D**) or TAZ (**E-H**) and DAPI (not shown). **I,J,** Quantification of nuclear to cytoplasmic ratio of YAP (**I**) or TAZ (**J**) with VEGF treatment. Nuclear/cytoplasmic ratio \> 1, YAP/TAZ nuclear; nuclear/cytoplasmic \< 1, YAP/TAZ cytoplasmic. At least 200 cells quantified.](elife-31037-resp-fig1){#respfig1}

The difference that we see in our experiments did not seem to be explained by the type of cells, confluency, culture conditions or starvation (Kim et al. (1) also used HUVECs -- confluent conditions -- EBM2 Lonza media, cells cultured in gelatine -- starvation 24h pure EBM2). However, we cannot exclude differences due to the nature or source of VEGF used. We used a commercial VEGF (murine VEGF165 from Prepotech) (and confirmed it's bioactivity by WB to pVEGFR2/VEGF and pERK/ERK -- not shown), while in Kim et al. (1) the origin of the VEGF is not specified and in Wang et al. (2) the VEGF used comes from Carmeliet's lab. It is possible then that the source of VEGF is critical to interpret these conflicting results. Without the missing information on nature (isoform) and source of VEGF in the papers by Wang and Kim, it will not be possible to test the reproducibility of their results. Critically, we find that despite the clear activation of VEGFR2 we see no evidence for activation of YAP or TAZ.

> 2\) The VE-cadherin turnover needs to be better analysed. There is a body of evidence in the literature demonstrating that VE-cadherin internalization is key to increase vascular permeability in vitro and in vivo (Gavard and Gutkind, Nat. Cell Biol. 2006, 8:1223-1234; Gavard et al., Dev. Cell 2008, 14:25-36; Dwyer et al., Oncogene 2011, 30:190-200; Orsenigo et al., Nat. Commun. 2012, 3:1208; Yoshioka et al., Nat. Med. 2012, 18:1560-1569; Wessel, F. et al., Nat. Immunol. 2014, 15:223-230; Dorland et al., Nat. Commun. 2016, 7:12210; Di Russo et al., EMBO J. 2017, 36: 183-201). The observation that YAP/TAZ knockdown would increase endothelial cell permeability and at the same time reduce VE-cadherin endocytosis appears difficult to be reconciled in light of the above mentioned papers.
>
> The problem is that pulse-chase experiments provide only a semi-quantitative analysis of the VE-cadherin turnover at cell-cell contacts rather than a quantitative analysis VE-cadherin endocytosis or recycling. FRAP experiments may be a more precise quantitative approach to evaluate VE-cadherin turnover at cell-cell junctions in YAP/TAZ-depleted HUVECs. We also advise to characterise the colocalization of VE-cadherin with markers of early and/or late endosomes, such as EEA1 or LAMP1, respectively.

As suggested by the reviewers, we performed quantitative analysis of the VE-Cadherin turnover by fluorescence loss after photoconversion. When evaluating the best method to quantify VE-Cadherin turnover, we discovered that FRAP suffers from uncertainty when junctions move during the measurement. This happens frequently in endothelial cells. Therefore, we established VE-Cadherin tagged with photoconvertible mEos, allowing to quantify the loss of fluorescence after conversion of a subset of molecules, whilst monitoring location of the unconverted molecules. Using this method, we observed an increase in the immobile fraction of VE-Cadherin at the junction after YAP/TAZ knockdown (new [Figure 5](#fig5){ref-type="fig"}). This result corroborates and explains our previous observations in the pulse-chase experiments that showed decreased VE-Cadherin turnover.

As pointed out by the referees, our results showing increased permeability together with decreased endocytosis were surprising and conflicting with current concepts. To gain more insight into cause and potential mechanisms, we repeated the experiment as suggested, by doing co-staining with the endocytosis markers EEA1 and LAMP1.

To ensure that we studied internalised VE-Cadherin, we pulse labeled cells with the VE-cadherin 55/7H1 at 4C, allowed 30 min of internalization at 37C and performed an acid wash prior to fixing the cells to remove cell surface bound antibody. Acid wash treatment removed most of cell surface bound antibody, including junctional VE-Cadherin. In this baseline condition prior to challenging the junctions with calcium chelation, control and YAP/TAZ depleted cells showed no obvious differences in amount or localization of pulsed VE-cadherin staining ([Author response image 2](#respfig2){ref-type="fig"}). Calcium chelation with EGTA led to dramatic internalization of VE-Cadherin in control cells, but very little after knockdown of YAP and TAZ, confirming our previous results.

![Acid wash treatment removes cell surface bound antibody.\
HUVECs knocked down for YAP/TAZ (E-H) and control (A-D) were pulse labelled with VE-cadherin 55/7H1 for 30 mins at 4C and internalisation was allowed for 30 min at 37C in the presence of 5mM EGTA (B, D, F, H) or vehicle (A, C, E, G). Acid wash treatment (C, D, G, H) removes cell surface antibody revealing internalised VE-cadherin 55/7H1. Scale bar 50μm.](elife-31037-resp-fig2){#respfig2}

Before EGTA treatment, the early endosome marker EEA1 co-localised with the internalized VE-cadherin in both control and YAP/TAZ deficient cells ([Author response image 3](#respfig3){ref-type="fig"}). However, we did not observe a co-localisation with LAMP1 (not shown). Interestingly, upon calcium chelation the dramatically internalized VE-cadherin did not appear in vesicles and did not co-localise with EEA1 ([Author response image 3](#respfig3){ref-type="fig"}); instead, VE-cadherin was found as a belt around the nucleus, and in some cells with a filamentous pattern. These results suggest that the mechanism of internalization associated with the well-studied permeability process and that after calcium chelation are different processes.

![Internalised VE-cadherin 55/7H1 co-localises with EEA1 in normal conditions, but not after disruption of cell junctions by calcium depletion.\
HUVECs knocked down for YAP/TAZ (B, D) and control (A, C) were pulse labelled with VE-cadherin 55/7H1-A647 (red) for 30 min at 4C and internalisation was allowed for 30 min at 37C in the presence of 5mM EGTA (C, D) or vehicle (A, B). Acid wash treatment was performed prior to fixing cells. Cells were co-stained with the early endosome marker EEA1 (green) and nuclei marker DAPI (blue). Yellow arrowheads, co-localisation of VE-cadherin 55/7H1-A647 with EEA1. Scale bar A-D, 10μm, A'-D', 5μm.](elife-31037-resp-fig3){#respfig3}

Going back to the original discoveries of adherens junction dependence on calcium, we noticed that a similar pattern was observed in MDCK cells: upon calcium depletion adherens junction proteins together with actin filaments retract centripetally to a perinuclear position, and are not associated with membrane material (3-5). As such, instead of addressing VE-Cadherin endocytosis, these results instead suggest that in YAP/TAZ deficient cells adherens junctions are under less tension -- either less actomyosin tension from the cytoskeleton or less linked to the actomyosin cytoskeleton. Interestingly, Kim et al. reported reduced phospho-myosin light chain 2 staining, indicating reduced tension in YAP/TAZ depleted endothelial cells (1). Our own f-actin staining showed strongly reduced branched actin networks and increased bundled actin at junctions in YAP/TAZ deficient cells, consistent with the observed changes in junctional patterning (new [Figure 5](#fig5){ref-type="fig"}). Together, these new results provide no evidence for altered endocytosis of VE-Cadherin, but confirm the reduced VE-cadherin turnover associated with altered junctional morphology in YAP/TAZ deficient endothelial cells. We propose it is this altered morphology together with reduced junction plasticity that is the cause for increased permeability.

> 3\) We find the YAP/TAZ link interesting, although such a link has recently been proposed by Totaro et al. (2017). The role of Notch and its epistatic relationship with YAP and/or TAZ should be somehow tackled experimentally, at least in vitro, and demonstrated not in all but at least in few key experiments. There are good reagents to manipulate Notch in cell culture and to couple it as downstream effector of YAP/TAZ (at least partially). The authors should also consider to test whether Notch serves as a mechanical mediator of (some) YAP/TAZ biology for endothelial cells.

As we found Notch signaling to be repressed in cells with forced nuclear YAP or TAZ, and increased Notch signaling in YAP/TAZ deficient cells, we hypothesized that a Notch signaling increase could be responsible for the hyposprouting phenotype in *Yap*^fl/fl^ *Taz*^fl/fl^ *Pdgfb-iCreERT2.* However, the data from Kim et al. already argue against this hypothesis as treatment of YAP/TAZ endothelial mutant mice with DAPT (to inhibit Notch signalling) did not rescue the phenotype (1). Similarly, when testing the hypothesis further, we found that the in vitro treatment of YAP/TAZ deficient cells with DBZ was able to rescue the Notch signalling increase, but did not rescue the migration defect in the scratch wound assay (new [Figure 8](#fig8){ref-type="fig"}). The fact that recent literature links stronger Notch activity to reduced endothelial permeability (6), and yet we find increased permeability in YAP/TAZ loss of function conditions, also raises doubts whether the observed Notch increase is indeed a driver of the YAP/TAZ phenotype. Thus Notch signalling may not be the critical signalling pathway downstream of YAP/TAZ regulating behaviour in endothelial cells.

We then tested if the strong increase in BMP signalling in YAP/TAZ deficient cells was responsible for the phenotype. We found that a partial rescue in BMP signalling in vitroimproved the cell migration defect and corrected the permeability defect; it also rescued the increase in finger junctions in YAP/TAZ deficient cells. As we could not completely rescue the signalling deregulation in YAP/TAZ deficient cells, we can only conclude from our experiments that BMP signalling is at least partially responsible for the phenotype of YAP/TAZ loss. Our microarray data on YAP and TAZ gain of function mutant cells further showed that YAP and TAZ regulate the transcription of several BMP inhibitors, providing a plausible mechanistic link between YAP/TAZ and BMP signalling. The new data is included in [Figure 8](#fig8){ref-type="fig"} and [Figure 8---figure supplement 1](#fig8s1){ref-type="fig"}. We have amended the discussion accordingly.

\[Editors\' note: further revisions were requested prior to acceptance, as described below.\]

> The manuscript has been improved but there are some remaining issues that need to be addressed before acceptance. In light of a recent paper published by the Schnittler lab in Nat. Commun., 2017, we would appreciate if you make the following changes in the text:

We have read and discussed the recent paper by the Schnittler lab in Nat. Comm. 2017 in depth in our team and we agree that it is an important piece of work, presenting data that relates to our own work and even supports our hypothesis. Specifically, Cao *et al.* were the first to identify the presence of junction associated intermediate lamellipodia (JAIL) in sprouting endothelial cells in vivo, thereby expanding the significance of these structures that to our knowledge had only been studied in cultured cells before, and so proving that their existence is not only an adaptation to the artificial in vitro culture system. Importantly, Cao *et al.* show that JAILs are present in sprouting endothelial cells (of the mouse retina and in the developing yolk sac), while they were not found in mature vessels. This strongly suggests that JAILs are characteristic of newly forming and highly dynamic angiogenic blood vessels. Therefore, the data from Cao *et al.* and our present work together would support a model in which decreased VE-Cadherin content at sprouting endothelial cells drives YAP and TAZ to the nucleus, where they increase the turnover of VE-Cadherin and increase the formation of JAILs, promoting cell migration and rearrangements. We have now included the reference Cao *et al.* 2017 and discuss the implications.

However, the very specific instructions of what to place in the Introduction of our manuscript and of adopting the terminology from Cao *et al.* throughout are problematic. After very careful consideration, we strongly feel that it is not appropriate or in the best interest of science to do so. In the following we explain our concerns and provide a point-by-point response:

> 1\) Explain in the Introduction section that two classes of VE-cadherin-based adhesions exist: adherent junctions (characterizing endothelial cells of mature and already formed blood vessels) and JAILs (typical of endothelial cells of newly forming and very dynamic angiogenic blood vessels).

We don't agree with this classification of VE-Cadherin based adhesions. Cell-cell junctions belong to one of three main categories: adherens junctions (AJ), tight junctions (TJ) and desmosomes. While in epithelial cells AJ and TJ are spatially separated, in the endothelium, with its characteristic flatness, this is not the case. In spite of that, AJ can be defined not only by (7) their spatial location in cell but also by (8) their molecular composition -- the main components of adherens junctions are the cadherin molecules. Depending on the type of cell, AJ assume different morphologies: in polarised epithelial AJ is also called adhesion belt as it completely encloses the cells along with the F-actin lining; in fibroblasts AJ are discontinuous, and in neurons they are organized into tiny puncta as a constituent of the synaptic junctions (7). AJ in endothelial cells have been extensively studied and it was observed that there are different morphologies in endothelial cells -- A) continuous/ linear/ straight junctions B), discontinuous/ fingers/serrated junctions and more recently also C) JAILs (8) (for illustration see [Author response image 4](#respfig4){ref-type="fig"}). We therefore place JAIL as a subcategory of AJ, and not as a new category of VE-Cadherin based adhesions. These distinct morphological categories are associated with actin filaments in particular ways: continuous junctions overlap a bundled actin filament, discontinuous junctions are linked to actin filaments perpendicular to the junction border, and JAIL are linked to branched actin on the dependence of ARP2/3 activity. How these morphologies relate to the behaviour of the endothelial cells has been extensively investigated along with their description, but not often in vivo. Studies in the developing mouse retina vasculature have shown that continuous/ linear/ straight junctions were associated with stalk cell behaviour, while discontinuous/ fingers/serrated junctions were found in tip cells or actively rearranging cells (9). To this model, the new data from Cao *et al.* adds JAIL as a new category characteristic of sprouting, actively rearranging cells \[added to the manuscript in line 210, highlighted in red\]. A general new categorisation that sets JAIL apart from AJ would seem premature and we feel it is more correct to add JAIL as a new subcategory of AJ.

![](elife-31037-resp-fig4){#respfig4}

> 2\) Adopt the Schnittler nomenclature throughout the manuscript by re-defining their \"reticular junctions\" as \"large JAILs\" and \"thick to reticular junctions\" as \"small JAILs\" (as also mentioned by authors in subsection "YAP/TAZ regulate adherens junction morphology and stability"). This will allow readers to more easily compare the complementary concepts exposed in these manuscripts.

An aspect that was raised already during this work and more so with this revision request it that the field of vascular biology will highly benefit from a consensus in nomenclature for adherens junctional categories. However, we believe it is important to most accurately describe the data in the Results section, without binning them into categories with assumed functions. For that reason, we defined the categories in morphological terms. Only subsequently, with live imaging, we were able to correspond thick to reticular and reticular junctions as small and large JAIL.

One important and novel aspect shown by Cao *et al.* by the use of live imaging is that these categories are not static. In fact, JAILs develop on top of continuous/ linear/ straight junctions and also on top of discontinuous/ fingers/ serrated junctions. In our work however, we characterized the morphology of AJ based on static data only. Because of this, we also caught what by live imaging data are clearly intermediate morphologies -- as thick junctions and thick to reticular junctions.

In the paper from Cao *et al.,* endothelial cells are polarised by means of scratching a monolayer or by treatment with VEGF, so that they display lateral junctions and leading and trailing edge junctions. Cao *et al.* observed that, in polarised endothelial cells, lateral junctions associated with small JAIL and leading edge junctions associated with large JAIL. In our manuscript however, we did not analyse VE-Cadherin morphologies after polarising cells, so they do not display lateral and polar junctions. Our thick to reticular/small JAILs can be fully developed JAIL of smaller size or a developing or retracting JAIL or larger size. In this sense, adopting the Schnittlernomenclature would be overreaching the data -- when we refer to small and large JAILs we refer to the size only, whereas they refer to a location in a polarized cell that is associated either with straight junctions or fingers (small JAIL -- lateral junction -- develops on top of straight junction and large JAIL -- leading edge junction -- develops on top of fingers). We propose that it is best to retain the strict morphology categories that can be directly connected to what the reader can see in the Results section. However, to embed the findings and provide functional interpretation and discussion, we refer to JAIL as discussion points.

> 3\) Mention that the preferential nuclear YAP/TAZ localization in endothelial cells of the sprouting front of the developing retinal vasculature nicely fit with the observation reported by Cao et al. (Nat. Commun., 2017, 8:2210). Indeed, in [Figure 1](#fig1){ref-type="fig"} Cao et al. show that endothelial cells of blood vessels localized at the sprouting front of the developing retina are elongated and display a reduced relative VE-cadherin concentration that promotes cell-to-cell junction dynamics and JAIL formation. Altogether, these data would provide additional strength to a model in which reduction of VE cadherin concentration at endothelial cell-to-cell junctions may promote YAP and TAZ relocation to the nucleus.

We have done so in the Discussion section, paragraph two.
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